Sentence,class,file
Mol Cancer Ther 2010; 9:347-57; PMi D:20124459; http://dx.doi.org/10.1158/1535- 7163.MCT-09-0872.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
eMBO Mol Med 2012; 4:515- 27; PMiD:22416035; http://dx.doi.org/10.1002/ emmm.201200229.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Blood 2010; 116:4578-87; PMiD:20739657; http://dx.doi.org/10.1182/blood- 2010-01-265769.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cancer Res 2011; 71:2632-42;  PMi D:21300766; http://dx.doi.org/10.1158/0008- 5472.CAN-10-1120.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cell Cycle 2012; 11:3837- 50; PMiD:22983061; http://dx.doi.org/10.4161/ cc.22026.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Proc Natl Acad Sci USA 2011; 108:3406-11; PM iD:21300883; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"J Clin Oncol 2011; 29:2843-4;  PMiD:21670452; http://dx.doi.org/10.1200/ JCO.2011.35.9208.Predicting PARP inhibitor sensitivity and resistance   Comment on: Oplustilova L, et al.",OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"Cell Cycle 2012; 11:3837–50;   PMID:22983061; http://dx.doi.org/10.4161/cc.22026 D. Gwyn Bebb1,2 and Susan P .",OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"Lees-Miller2,3; 1Division of Medical Oncology; Tom Baker Cancer Centre; Calgary, AB Canada; 2Southern Alberta Cancer Research  Institute; Calgary, AB Canada; 3Departments of Biochemistry & Molecular Biology and Oncology; University of Calgary; Calgary, AB Canada;   Email: Gwyn.Bebb@albertahealthservices.ca and leesmill@ucalgary.ca; http://dx.doi.org/10.4161/cc.22604",Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Annu Rev Genet 2011; 45:247- 71; PMiD:21910633; http://dx.doi.org/10.1146/ annurev-genet-110410-132435.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Science 2003; 300:1542-8; PMiD:12791985; http://dx.doi.org/10.1126/sci- ence.1083430.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Proc Natl Acad Sci USA 1995;  92:7642-6; PM iD:7644470; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Nature 2001; 412:456-61; PMiD:11473323; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Nature 2010; 467:112-6; PMiD:20811461; http://dx.doi.org/10.1038/ nature09355.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Nature 2010; 467:108-11; PMiD:20811460; http://dx.doi.org/10.1038/ nature09318.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cancer Res 2012; 72:2802-13; PMi D:22491672; http://dx.doi.org/10.1158/0008- 5472.CAN-11-3152.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cell Cycle 2012; 11:3983-96;  PMiD:22987153; http://dx.doi.org/10.4161/ cc.22215.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"Genes Dev 2012; 26:1393-408; PMiD:22751496; http://dx.doi.org/10.1101/ gad.195248.112.Examining the roles of DNA2 during mammalian end resection Comment on: Karanja KK, et al.",OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"Cell Cycle 2012; 11:3983–96;   PMID:22987153; http://dx.doi.org/10.4161/cc.22215 Jeremy M. Stark and Binghui Shen; Department of Radiation Biology; City of Hope National Medical Center and Beckman Research Institute; Duarte, CA USA;   Email: jstark@coh.org and bshen@coh.org; http://dx.doi.org/10.4161/cc.22605",OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"Cell Cycle 2012; 11:4181–90;   PMID:23095642; http://dx.doi.org/10.4161/cc.22413  Swathi V. Iyer and Tomoo Iwakuma*; Department of Cancer Biology; University of Kansas Medical Center; Kansas City, KS USA;  *Email: tiwakuma@kumc.edu; http://dx.doi.org/10.4161/cc.22606 The constitutive photomorphogenesis 9  (COP9) signalosome (CSN) is an evolutionarily conserved multiprotein complex in plants and animals.",OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cell Cycle 2012; 11:4059–68;   PMID:23095493; http://dx.doi.org/10.4161/cc.22381  Yifan Wang and Binhua P .,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"Zhou*; Department of Molecular and Cellular Biochemistry and Markey Cancer Center; University of Kentucky School of Medicine;  Lexington, KY USA; *Email: peter.zhou@uky.edu; http://dx.doi.org/10.4161/cc.22607References 1.",Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Annu Rev Cell Dev Biol 2003; 19:261- 86; http://dx.doi.org/10.1146/annurev.cell- bio.19.111301.112449; PMiD:14570571.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Mol Oncol 2012; 6:267-75; http://dx.doi.org/10.1016/j.molonc.2012.01.003;  PMiD:22306028.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cycle 2011; 10:3057-66; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
FeBS Lett 2012; 586:1390-6; http://dx.doi.org/10.1016/j.febslet.2012.02.049;  PMiD:22673503.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"J Biol Chem 2004; 279:35510-7; http://dx.doi.org/10.1074/jbc.M404936200;  PMiD:15169778.8. eroles P , et al.",OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Cancer Treat Rev 2012; 38:698- 707; http://dx.doi.org/10.1016/j.ctrv.2011.11.005;  PMiD:22178455.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Mol Cancer Res 2007; 5:1-10; http://dx.doi.org/10.1158/1541-7786.MCR-06-0208;  PMiD:17259342.,Non-OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
Nature 2004; 428:77-81; http://dx.doi.org/10.1038/nature02313; PMiD:14999283.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
J Biol Chem 2011; 286:2236-44; http://dx.doi.org/10.1074/jbc.M110.174755;  PMiD:20959462.,OADS,/arxiv_data1/oa_pdf/57/d3/cc-11-4113.PMC3524204.pdf
"*Correspondence to: Giuseppe Maulucci and Giovambattista Pani; Email:  giuseppe.maulucci@rm.unicatt.it and gpani@rm.unicatt.itSubmitted: 08/27/12; Accepted: 09/04/12http://dx.doi.org/10.4161/cc.22074sirt1, the closest mammalian homolog of the sir2 yeast long- evity protein, has been extensively investigated in the last  few years as an avenue to understand the connection linking  nutrients and energy metabolism with aging and related  diseases.",Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
N Engl J Med 2011;  364:2235-44; PMID:21651395; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2010; 328:321- 6; PMID:20395504; http://dx.doi.org/10.1126/sci- ence.1172539.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2005; 120:473-82; PMID:15734680;  http://dx.doi.org/10.1016/j.cell.2005.01.029.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
T rends Endocrinol Metab 2009; 20:325- 31; PMID:19713122; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Commun 2010;  1:3; PMID:20975665; http://dx.doi.org/10.1038/ ncomms1001.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature  2009; 460:587-91; PMID:19641587; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell Metab  2012; 15:675-90; PMID:22560220; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
IUBMB Life 2009; 61:1010-1; PMID:19787705; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2006; 444:337- 42; PMID:17086191; http://dx.doi.org/10.1038/ nature05354.14.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell  2006; 127:1109-22; PMID:17112576; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2012; 483:218-21;  PMID:22367546; http://dx.doi.org/10.1038/ nature10815.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Aging  Cell 2007; 6:759-67; PMID:17877786; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2005; 310:314-7; PMID:16224023;  http://dx.doi.org/10.1126/science.1117728.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2003; 425:132-3; PMID:12968159; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature  2000; 403:795-800; PMID:10693811; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2009; 459:802- 7; PMID:19516333; http://dx.doi.org/10.1038/nature08085.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol Cell 2004; 16:93-105;  PMID:15469825; http://dx.doi.org/10.1016/j.mol- cel.2004.08.031.26.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol Cell Biol 2003; 23:38-54;  PMID:12482959; http://dx.doi.org/10.1128/ MCB.23.1.38-54.2003.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2007; 450:440-4; PMID:18004385; http://dx.doi.org/10.1038/nature06268.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Cell Biol 2008; 10:385- 94; PMID:18344989; http://dx.doi.org/10.1038/ ncb1700.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol  Cell 2003; 12:51-62; PMID:12887892; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Exp  Gerontol 2012; 47:229-36; PMID:22226624; http://dx.doi.org/10.1016/j.exger.2011.12.009.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem  2005; 280:10264-76; PMID:15632193; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2001; 107:149-59;  PMID:11672523; http://dx.doi.org/10.1016/S0092- 8674(01)00527-X.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Clin Invest 2011; 121:4281- 8; PMID:21985785; http://dx.doi.org/10.1172/ JCI58554.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2006; 444:860-7; PMID:17167474;  http://dx.doi.org/10.1038/nature05485.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell Metab 2011; 14:612- 22; PMID:22055504; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Blood 2010; 115:965-74; PMID:19996091; http://dx.doi.org/10.1182/blood- 2009-02-207118.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Rev Mol Cell Biol 2011; 12:141-51;  PMID:21346730; http://dx.doi.org/10.1038/ nrm3072.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Neuron 2000; 25:11-4;  PMID:10707967; http://dx.doi.org/10.1016/S0896- 6273(00)80866-1.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell Metab 2011; 14:758- 67; PMID:22078933; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Circ Res 2007; 100:1512- 21; PMID:17446436; http://dx.doi.org/10.1161/01.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Genes Dev 2008; 22:1753- 7; PMID:18550784; http://dx.doi.org/10.1101/gad.1650608.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Med  2012; 18:159-65; PMID:22179316; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Genes Dev  2009; 23:2812-7; PMID:20008932; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2010; 466:1105- 9; PMID:20622856; http://dx.doi.org/10.1038/ nature09271.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2005; 307:375-9; PMID:15662002;  http://dx.doi.org/10.1126/science.1104344.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Clin Pract Endocrinol Metab 2009;  5:160-6; PMID:19229236; http://dx.doi.org/10.1038/ ncpendmet1070.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
EMBO J  2007; 26:1913-23; PMID:17347648; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem  2005; 280:16456-60; PMID:15716268; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2006; 127:397-408; PMID:17055439;  http://dx.doi.org/10.1016/j.cell.2006.09.024.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Proc Natl Acad Sci USA 2012; 109:621-6; PMID:22190495; http://dx.doi.org/10.1073/ pnas.1109237109.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol Cell 2007; 28:91-106;  PMID:17936707; http://dx.doi.org/10.1016/j.mol- cel.2007.07.032.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2009; 324:1289-93;  PMID:19498162; http://dx.doi.org/10.1126/sci- ence.1169956.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem  2011; 286:13869-78; PMID:21345792; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Cell  Biol 2003; 5:741-7; PMID:12855956; http://dx.doi.org/10.1038/ncb1024.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
EMBO J 2004; 23:2369-80; PMID:15152190;  http://dx.doi.org/10.1038/sj.emboj.7600244.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Cell Biol  2009; 11:492-500; PMID:19295512; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2001; 107:137-48;  PMID:11672522; http://dx.doi.org/10.1016/S0092- 8674(01)00524-4.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Proc Natl Acad Sci USA 2003; 100:10794- 9; PMID:12960381; http://dx.doi.org/10.1073/ pnas.1934713100.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2008; 451:583-6; PMID:18235501;  http://dx.doi.org/10.1038/nature06500.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2008; 451:587-90; PMID:18235502;  http://dx.doi.org/10.1038/nature06515.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2004; 306:2105-8; PMID:15604409;  http://dx.doi.org/10.1126/science.1101731.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2004; 116:551-63;  PMID:14980222; http://dx.doi.org/10.1016/S0092- 8674(04)00126-6.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science  2004; 303:2011-5; PMID:14976264; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Oncogene 2008; 27:2258-62; PMID:18391968;  http://dx.doi.org/10.1038/onc.2008.29.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem  2004; 279:28873-9; PMID:15126506; http://dx.doi.org/10.1074/jbc.M401138200.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2000;  408:255-62; PMID:11089983; http://dx.doi.org/10.1038/35041700.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2009; 458:1056- 60; PMID:19262508; http://dx.doi.org/10.1038/ nature07813.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nature 2004; 429:771- 6; PMID:15175761; http://dx.doi.org/10.1038/ nature02583.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Int J Obes (Lond) 2005;  29(Suppl 1):S36-9; PMID:15711582; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
FEBS Lett 2008; 582:46-53;  PMID:18036349; http://dx.doi.org/10.1016/j.febs- let.2007.11.034.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
FEBS Lett 2008; 582:2417-23;  PMID:18544345; http://dx.doi.org/10.1016/j.febs- let.2008.06.005.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Hum Mol Genet 2010; 19:4123- 33; PMID:20693263; http://dx.doi.org/10.1093/hmg/ ddq331.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Proc Natl Acad Sci USA 2007; 104:829- 33; PMID:17213307; http://dx.doi.org/10.1073/ pnas.0610590104.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
EMBO Rep 2011; 12:1069-76; PMID:21836635; http://dx.doi.org/10.1038/embor.2011.151.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Cell Biol 2006; 8:1025-31; PMID:16892051; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Cell Biol 2009; 185:203-11; PMID:19364925;  http://dx.doi.org/10.1083/jcb.200809167.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol Cell  2007; 25:543-57; PMID:17317627; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem  2010; 285:13223-32; PMID:20167603; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
PLoS ONE 2009; 4:e6611; PMID:19680552; http://dx.doi.org/10.1371/journal.pone.0006611.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
PLoS ONE 2009; 4:e8414; PMID:20027304; http://dx.doi.org/10.1371/ journal.pone.0008414.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
PLoS ONE 2008; 3:e4020;  PMID:19107194; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Neurosci 2010; 30:5394- 403; PMID:20392961; http://dx.doi.org/10.1523/ JNEUROSCI.5831-09.2010.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nat Genet 2005; 37:349-50;  PMID:15793589; http://dx.doi.org/10.1038/ng1534.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2010; 142:320- 32; PMID:20655472; http://dx.doi.org/10.1016/j.cell.2010.06.020.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Dev Cell  2008; 14:661-73; PMID:18477450; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2009; 324:654- 7; PMID:19286518; http://dx.doi.org/10.1126/sci- ence.1170803.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2009; 324:651-4; PMID:19299583;  http://dx.doi.org/10.1126/science.1171641.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2008; 134:212- 4; PMID:18662537; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Prog Neurobiol  2007; 82:142-50; PMID:17482337; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Proc Natl Acad Sci USA 2012; 109:E187-96; PMID:22190494; http://dx.doi.org/10.1073/ pnas.1105304109.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Science 2004; 305:1010-3;  PMID:15310905; http://dx.doi.org/10.1126/sci- ence.1098014.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Cell Biol  2005; 170:349-55; PMID:16043516; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol Cell 2007; 28:277-90;  PMID:17964266; http://dx.doi.org/10.1016/j.mol- cel.2007.08.030.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
PLoS ONE 2008; 3:e2020; PMID:18414679;  http://dx.doi.org/10.1371/journal.pone.0002020.87.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell 2011; 147:728-41;  PMID:22078875; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Mol Cell 2007; 27:149-62;  PMID:17612497; http://dx.doi.org/10.1016/j.mol- cel.2007.05.029.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Biochem Biophys Res Commun  2009; 390:1355-60; PMID:19895790; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Nucleic Acids Res 2010; 38:832-45; PMID:19934257;  http://dx.doi.org/10.1093/nar/gkp1039.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem 2012; 287:3850- 8; PMID:22157007; http://dx.doi.org/10.1074/jbc.M111.317404.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Neuron  2010; 67:953-66; PMID:20869593; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
PLoS Biol 2010; 8:e1000372;  PMID:20502519; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
J Biol Chem  2011; 286:22227-34; PMID:21540183; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Curr  Opin Pharmacol 2009; 9:753-62; PMID:19683471;  http://dx.doi.org/10.1016/j.coph.2009.07.004.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell Metab  2007; 6:307-19; PMID:17908559; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
Cell Metab 2008; 8:38- 48; PMID:18590691; http://dx.doi.org/10.1016/j.cmet.2008.05.004.,OADS,/arxiv_data1/oa_pdf/63/7a/cc-11-4135.PMC3524209.pdf
"Cell Cycle 11:22, 4222–4241; November 15, 2012; © 2012 Landes Bioscience RepoR t 4222 Cell Cycle Volume 11 Issue 22*Correspondence to: Alexey Moskalev; Email: amoskalev@ib.komisc.ru Submitted: 10/06/12; Accepted: 10/12/12http://dx.doi.org/10.4161/cc.22545Introduction Proteins of the GADD45 (growth-arrest and DNA damage  inducible 45) family take part in gene expression regulation, cell cycle arrest, DNA repair and apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/3d/f3/cc-11-4222.PMC3524218.pdf
"Cell Cycle 11:22, 4242–4251; November 15, 2012; © 2012 Landes Bioscience RepoR t 4242 Cell Cycle Volume 11 Issue 22*Correspondence to: Roberta Maestro; Email: rmaestro@cro.it Submitted: 09/05/12; Revised: 10/11/12; Accepted: 10/12/12http://dx.doi.org/10.4161/cc.22543Introduction Breast cancer is a heterogeneous disease, with distinct subtypes  characterized by different biology and response to therapy.",Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
J Clin Invest 2009; 119:1420- 8; PMID:19487818; http://dx.doi.org/10.1172/ JCI39104.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle 2010; 9:886-91; PMID:20160487;  http://dx.doi.org/10.4161/cc.9.5.10839.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Int J Cancer 2011; 129:2310- 4; PMID:21792896; http://dx.doi.org/10.1002/ ijc.26311.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cancer Lett 2012;  PMID:22634497; http://dx.doi.org/10.1016/j.can- let.2012.05.014.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Stem  Cell 2007; 1:555-67; PMID:18371393; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cancer Res 2009; 69:1302-13; PMID:19190339; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle 2008; 7:3112-8; PMID:18927505; http://dx.doi.org/10.4161/ cc.7.20.6851.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
J Mammary Gland Biol Neoplasia 2010; 15:235- 52; PMID:20521089; http://dx.doi.org/10.1007/ s10911-010-9175-z.10.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell 2009; 138:1083-95; PMID:19766563;  http://dx.doi.org/10.1016/j.cell.2009.06.048.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle 2011; 10:3751- 7; PMID:22033190; http://dx.doi.org/10.4161/cc.10.21.17921.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle 2012; 11:2691-8; PMID:22732500; http://dx.doi.org/10.4161/cc.21021.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Nat Genet 2008; 40:499-507;  PMID:18443585; http://dx.doi.org/10.1038/ng.127.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle 2008; 7:3622-4; PMID:19029796; http://dx.doi.org/10.4161/ cc.7.23.7104.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Proc Natl Acad Sci USA  2003; 100:3983-8; PMID:12629218; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
J Natl Cancer Inst 2006; 98:1777- 85; PMID:17179479; http://dx.doi.org/10.1093/jnci/ djj495.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
J Natl Cancer Inst 2010; 102:1637- 52; PMID:20935265; http://dx.doi.org/10.1093/jnci/ djq361.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Nature 2000; 406:747-52; PMID:10963602;  http://dx.doi.org/10.1038/35021093.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Proc Natl Acad Sci USA 2001; 98:10869- 74; PMID:11553815; http://dx.doi.org/10.1073/ pnas.191367098.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Oncologist 2010; 15(Suppl 5):39- 48; PMID:21138954; http://dx.doi.org/10.1634/theoncologist.2010-S5-39.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Breast Cancer Res 2010; 12:R68;  PMID:20813035; http://dx.doi.org/10.1186/bcr2635.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Breast Cancer Res 2008; 10:R53;  PMID:18559090; http://dx.doi.org/10.1186/bcr2108.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Clin Cancer Res 2010; 16:876-87;  PMID:20103682; http://dx.doi.org/10.1158/1078- 0432.CCR-09-1532.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Genes Dev 2003; 17:1253- 70; PMID:12756227; http://dx.doi.org/10.1101/ gad.1061803.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cancer Res 2007; 67:8131-8; PMID:17804725; http://dx.doi.org/10.1158/0008- 5472.CAN-06-4493.detected with anti-mouse and anti-rabbit secondary antibod - ies HRP-labeled (PerkinElmer) using Western Lightning™  Chemiluminescence Reagent Plus (PerkinElmer) by the imag - ing analyzer Chemidoc XRS+ (Biorad).,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle 2010; 9:623- 4; PMID:20107326; http://dx.doi.org/10.4161/ cc.9.4.10779.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cancer Metastasis Rev 2012; 31:131- 42; PMID:22101651; http://dx.doi.org/10.1007/s10555-011-9336-6.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Anal Biochem 2002; 307:304-15;  PMID:12202248; http://dx.doi.org/10.1016/S0003- 2697(02)00058-1.36.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Stem Cells 2012; 30:344- 8; PMID:22131125; http://dx.doi.org/10.1002/ stem.1001.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Stem Cells 2011; 29:32-45; PMID:21280157;  http://dx.doi.org/10.1002/stem.563.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Cycle  2011; 10:1378-84; PMID:21552008; http://dx.doi.org/10.4161/cc.10.9.15486.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Proc Natl Acad Sci USA 2012; 109:2742- 7; PMID:21969591; http://dx.doi.org/10.1073/ pnas.1106509108.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Mol Oncol  2007; 1:84-96; PMID:18516279; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell Death Differ 2011;  18:1470-7; PMID:21617693; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Cell  2008; 133:704-15; PMID:18485877; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Stem Cells 2010; 28:1081- 8; PMID:20506111; http://dx.doi.org/10.1002/ stem.435.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Proc Natl Acad Sci USA  2012; 109:2772-7; PMID:21940501; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Breast Cancer Res 2011; 13:R118; PMID:22112299; http://dx.doi.org/10.1186/bcr3061.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
Mod Pathol 2012; 25:388-97;  PMID:22080062; http://dx.doi.org/10.1038/mod- pathol.2011.172.,Non-OADS,/arxiv_data1/oa_pdf/59/99/cc-11-4242.PMC3524219.pdf
"Cell Cycle 11:22, 4266–4274; November 15, 2012; © 2012 Landes Bioscience RepoR t 4266 Cell Cycle Volume 11 Issue 22*Correspondence to: Vimla Band; Email: vband@unmc.edu Submitted: 08/20/12; Revised: 10/19/12; Accepted: 10/20/12http://dx.doi.org/10.4161/cc.22613Introduction DNA damage response (DDR) is essential for the maintenance  of genomic stability,1,2 and an unstable genome leads to accumu - lations of mutations and cancer development.",Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Science  2002; 297:547-51; PMID:12142523; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nature 2000;  408:433-9; PMID:11100718; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nat Genet  2001; 27:247-54; PMID:11242102; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol  Cell 2001; 8:1160-1; PMID:11885597; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Biochem J  2009; 423:157-68; PMID:19772495; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nature 2004; 432:316-23; PMID:15549093;  http://dx.doi.org/10.1038/nature03097.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/ nature08467.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Cold Spring Harb  Symp Quant Biol 2000; 65:489-98; PMID:12760066;  http://dx.doi.org/10.1101/sqb.2000.65.489.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Vet Pathol 1998; 35:461-78; PMID:9823588; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Cell 2007; 128:707-19;  PMID:17320508; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nature 1997; 389:251-60;  PMID:9305837; http://dx.doi.org/10.1038/38444.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Cell 2007; 128:693-705; PMID:17320507; http://dx.doi.org/10.1016/j.cell.2007.02.005.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell 2012; 45:710-8; PMID:22464441; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell  2005; 17:301-11; PMID:15664198; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nature 2000; 403:41-5;  PMID:10638745; http://dx.doi.org/10.1038/47412.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Annu Rev Biochem 2001; 70:81-120; PMID:11395403; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
T rends Genet 2003; 19:321-9; PMID:12801725;  http://dx.doi.org/10.1016/S0168-9525(03)00115-X.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell Biol  2010; 30:3582-95; PMID:20479123; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell Biol 2005; 25:5292- 305; PMID:15923642; http://dx.doi.org/10.1128/ MCB.25.12.5292-5305.2005.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell Biol 2009; 29:1176-88; PMID:19103755;  http://dx.doi.org/10.1128/MCB.01599-08.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Oncogene 2007; 26:5341-57; PMID:17694077;  http://dx.doi.org/10.1038/sj.onc.1210604.25.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
EMBO J 2010; 29:2381- 94; PMID:20562830; http://dx.doi.org/10.1038/ emboj.2010.125.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell Biol 2011; 31:190- 202; PMID:20956559; http://dx.doi.org/10.1128/ MCB.00317-10.,Non-OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Cell 2007; 128:721-33; PMID:17320509;  http://dx.doi.org/10.1016/j.cell.2007.01.030.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell  2010; 37:469-80; PMID:20188666; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nat  Struct Mol Biol 2009; 16:412-20; PMID:19343071;  http://dx.doi.org/10.1038/nsmb.1583.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell Biol 2002; 22:5801- 12; PMID:12138191; http://dx.doi.org/10.1128/MCB.22.16.5801-5812.2002.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
J Biol Chem 2007; 282:8812-20; PMID:17272277; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
J Biol Chem  2012; 287:29442-56; PMID:22736770; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
J Biol Chem  2010; 285:1097-104; PMID:19910469; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
J Cell Biol  1963; 17:299-313; PMID:13985244; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Genes Cells  1998; 3:789-800; PMID:10096020; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nat Cell Biol 2006;  8:91-9; PMID:16341205; http://dx.doi.org/10.1038/ ncb1343.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Mol Cell 2004; 16:979-90;  PMID:15610740; http://dx.doi.org/10.1016/j.mol-cel.2004.12.003.35.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
Nature  2008; 455:689-92; PMID:18716619; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
J Biol Chem 2009; 284:9558- 65; PMID:19202191; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
J Biol Chem 1997; 272:30595-8; PMID:9388189; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/8b/cc-11-4266.PMC3524221.pdf
"(Biochemistry, Microbiology and i mmunology); Faculty of  Medicine; University of o ttawa; o ttawa, o ntario, Canada; 3department of Medical Sciences; Northern o ntario School of Medicine; Sudbury, o ntario, Canada Keywords:  DNA replication origin, OBR, ABR, replication initiation point, lamin B2 ori *Correspondence to: Hoyun Lee; Email: hlee@hsnsudbury.ca Submitted: 08/08/12; Accepted: 08/27/12http://dx.doi.org/10.4161/cc.21992Contrarily to the OBR model, data from  2D replicon mapping demonstrated that replication initiates from almost any sites within the entire 55 kb inter - genic region of the CHO DHFR locus, 4,7  although data from another laboratory suggested an OBR exists in this locus.",Non-OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Nat Rev Genet 2010; 11:673-84;  PMID:20811343; http://dx.doi.org/10.1038/nrg2830.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Genome Res 2011; 21:1438-49; PMID:21750104; http://dx.doi.org/10.1101/ gr.121830.111.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Genome Res 2011; 21:377-89; PMID:21173031; http://dx.doi.org/10.1101/ gr.111328.110.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Cell 1990; 61:1075-87; PMID:2350784; http://dx.doi.org/10.1016/0092- 8674(90)90071-L. 5.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Cell 1990; 62:955-65;  PMID:2393905; http://dx.doi.org/10.1016/0092-8674(90)90270-O.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
"Science 2000; 287:2023- 6; PMID:10720330; http://dx.doi.org/10.1126/sci- ence.287.5460.2023.Bidirectional replication requires that  two separate sets of large replication com - plexes simultaneously bind to one specific  initiation site, which can be very challeng - ing.",Non-OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Mol Cell Biol 2003; 23:804- 14; PMID:12529386; http://dx.doi.org/10.1128/ MCB.23.3.804-814.2003.,Non-OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Nat Protoc 2008; 3:1729-35;  PMID:18927558; http://dx.doi.org/10.1038/nprot.2008.173.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Nat Struct Mol Biol 2008; 15:722- 9; PMID:18536724; http://dx.doi.org/10.1038/ nsmb.1439.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Nucleic Acids Res 2011; 39:3141-55; PMID:21148149; http://dx.doi.org/10.1093/nar/ gkq1276.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Curr Biol 2001; 11:1427-31; PMID:11566101; http://dx.doi.org/10.1016/S0960- 9822(01)00444-4.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
Proc Natl Acad Sci USA 1996; 93:1498-503; PMID:8643660; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ac/34/cc-11-4281.PMC3524223.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 EDITORIAL   Medicine General & Social Medicine Propofol Abuse in Professionals Jaemin Lee Department of Anesthesiology and Pain Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Koreahttp://dx.doi.org/10.3346/jkms.2012.27.12.1451   •  J Korean Med Sci 2012; 27: 1451-1452 Media attention on the abuse of propofol, which is also called  the “milk drug” or “white one” because of its typical white color,  has increased significantly in Korea since the drug was impli - cated in the death of a lover of a gynecologist in August 2012.",Non-OADS,/arxiv_data1/oa_pdf/60/33/jkms-27-1451.PMC3524421.pdf
Lee J • Propofol Abuse in Professionals 1452   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1451nea can persist for up to 3 min with a risk for irreversible and  potential lethal hypoxemia (14).,Non-OADS,/arxiv_data1/oa_pdf/60/33/jkms-27-1451.PMC3524421.pdf
7. http://www.hkn24.com/news/articleView.html?,Non-OADS,/arxiv_data1/oa_pdf/60/33/jkms-27-1451.PMC3524421.pdf
idxno=108467 8. http://www.nocutnews.co.kr/Show.asp?,Non-OADS,/arxiv_data1/oa_pdf/60/33/jkms-27-1451.PMC3524421.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 A New Disability Rating Method according to the Job Using   the Korean Academy of Medical Science Disability Guideline The purpose of this study was to develop a disability rating scale according to job  classification using the Korean Academy of Medical Society (KAMS) guidelines.",Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
"http://dx.doi.org/10.3346/jkms.2012.27.12.1453   •  J Korean Med Sci 2012; 27: 1453-1459ORIGINAL ARTICLE Medicine General & Social Medicine INTRODUCTION A disability rating is a monetary sum derived to reflect direct  economic losses, as well as noneconomic losses, and the im - pact on quality of life as a result of a medical impairment (1).",Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
"• A New Job-Adjusted Disability Rating Method using KAMS Disability Guideline 1454   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1453have their advantages and disadvantages, but practical applica - tion of either theory is difficult due to the excessive number of  variables.",Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
• A New Job-Adjusted Disability Rating Method using KAMS Disability Guideline http://jkms.org   1455  http://dx.doi.org/10.3346/jkms.2012.27.12.1453Final disability rate determination by occupation The final disability rate by occupation was determined using  the KAMS whole body impairment rate in conjunction with the  ODI.,Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
• A New Job-Adjusted Disability Rating Method using KAMS Disability Guideline 1456   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1453Comparison of occupational disability index by  occupation and body impairment rate The job-adjusted disability rate was plotted according to the  whole-body impairment rate in order to estimate the change in  body impairment rate according to the occupation considered.,OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
"• A New Job-Adjusted Disability Rating Method using KAMS Disability Guideline http://jkms.org   1457  http://dx.doi.org/10.3346/jkms.2012.27.12.1453rate based on the KAMS standard was relatively consistent, rang - ing from 0% to 18%, and showed the greatest change in the body  impairment rate ranging from 40% to 60% (Fig.",Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
• A New Job-Adjusted Disability Rating Method using KAMS Disability Guideline 1458   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1453for cases of physical damage such as car accidents.,Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
• A New Job-Adjusted Disability Rating Method using KAMS Disability Guideline http://jkms.org   1459  http://dx.doi.org/10.3346/jkms.2012.27.12.1453pensable Injuries.,Non-OADS,/arxiv_data1/oa_pdf/68/e1/jkms-27-1453.PMC3524422.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 The Clinical Course and Outcomes of Post-Transplantation  Diabetes Mellitus after Heart Transplantation The aim of this study was to describe in more detail the predisposition, natural course, and  clinical impact of post-transplantation diabetes mellitus (PTDM) after heart transplantation  (HT).",Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
"Key Words:  PTDM; Heart Transplantation; Prognosis; Cardiac Allograft VasculopathyMin Soo Cho1, Hyo-In Choi1, In-Ok Kim2,  Sung-Ho Jung3, Tae-Jin Yun3,  Jae-Won Lee3, Min-Seok Kim1,  and Jae-Joong Kim1   1Department of Internal Medicine, 2Organ  Transplantation Program, 3Department of Cardiac  Surgery, Asan Medical Center, University of Ulsan  College of Medicine, Seoul, Korea  Received: 31 May 2012 Accepted: 13 September 2012 Address for Correspondence: Jae-Joong Kim, MD Department of Internal Medicine, Asan Medical Center,  University of Ulsan College of Medicine, 88 Olympic-ro 43-gil,  Songpa-gu, Seoul 138-736, Korea Tel: +82.2-3010-3154, Fax: +82.2-486-5918 E-mail: jjkim@amc.seoul.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1460   •  J Korean Med Sci 2012; 27: 1460-1467ORIGINAL ARTICLE  Cell Therapy & Organ Transplantation INTRODUCTION From the early days of transplantation, post-transplantation di - abetes mellitus (PTDM) has been recognized as a major com - plications of solid organ transplantation.",Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation http://jkms.org   1461  http://dx.doi.org/10.3346/jkms.2012.27.12.1460Diagnosis of PTDM PTDM was diagnosed using the American Diabetes Associa - tion criteria (14).,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation 1462   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1460RESULTS Baseline characteristics Patient characteristics are summarized in Table 1.,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation http://jkms.org   1463  http://dx.doi.org/10.3346/jkms.2012.27.12.1460patient visit was 8.1% ±1.8% and decreased to 6.9% ±0.9% at  one year and 7.0% ±0.9% at their last follow-up.,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation 1464   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1460ble 4).,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation http://jkms.org   1465  http://dx.doi.org/10.3346/jkms.2012.27.12.1460(1.3±0.6 vs 1.1 ±0.4 mg/dL) were not significantly different.,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation 1466   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1460on vasculopathy or rejection in our patients.,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
• Post-Transplantation Diabetes Mellitus after Heart Transplantation http://jkms.org   1467  http://dx.doi.org/10.3346/jkms.2012.27.12.146020.,Non-OADS,/arxiv_data1/oa_pdf/df/e7/jkms-27-1460.PMC3524423.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Risk Factors for Febrile Neutropenia during Chemotherapy for  HIV-Related Lymphoma We evaluated risk factors for neutropenic fever and febrile prolonged neutropenia during  vincristine-including chemotherapy to treat HIV-related lymphoma to investigate whether  protease inhibitor (PI) treatment is associated with infectious complications due to drug  interactions with chemotherapeutic agents.",Non-OADS,/arxiv_data1/oa_pdf/11/31/jkms-27-1468.PMC3524424.pdf
"Key Words:  Human Immunodeficiency Virus; Lymphoma; NeutropeniaJinyong Park*, Tae Min Kim,   Jeong-Hwan Hwang, Nak-Hyun Kim,   Pyoeng Gyun Choe, Kyoung-ho Song,   Eu Suk Kim, Sang-Won Park,   Hong Bin Kim, Nam Joong Kim,   Wan Beom Park, and Myoung-don Oh Department of Internal Medicine, Seoul National  University College of Medicine, Seoul, Korea *Present address: Department of Internal Medicine,  Incheon Sarang Hospital, 726 Michuhol-daero,  Nam-gu, Incheon 402-835, Korea Received: 27 January 2012 Accepted: 20 September 2012 Address for Correspondence: Wan Beom Park, MD Department of Internal Medicine, Seoul National University  College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 1 10-744,  Korea Tel: +82.2-2072-3596, Fax: +82.2-762-9662 E-mail: wbpark1@snu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1468   •  J Korean Med Sci 2012; 27: 1468-1471ORIGINAL ARTICLE   Infectious Diseases, Microbiology & Parasitology INTRODUCTION Lymphoma is an important malignancy in the morbidity and  mortality of HIV patients, although its incidence began to de - crease after the introduction of combined antiretroviral therapy  (1).",Non-OADS,/arxiv_data1/oa_pdf/11/31/jkms-27-1468.PMC3524424.pdf
• Neutropenic Fever in HIV-Related Lymphoma  http://jkms.org   1469  http://dx.doi.org/10.3346/jkms.2012.27.12.1468< 500 cells/µL on two occasions with axillary temperature over  38°C for ≥ 1 hr.,Non-OADS,/arxiv_data1/oa_pdf/11/31/jkms-27-1468.PMC3524424.pdf
"• Neutropenic Fever in HIV-Related Lymphoma  1470   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.14681.01-1.12) and high-risk regimens (aOR 46.9; 95% CI, 4.22-521.89)  were associated with febrile illness with prolonged neutropenia.",Non-OADS,/arxiv_data1/oa_pdf/11/31/jkms-27-1468.PMC3524424.pdf
• Neutropenic Fever in HIV-Related Lymphoma  http://jkms.org   1471  http://dx.doi.org/10.3346/jkms.2012.27.12.1468REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/11/31/jkms-27-1468.PMC3524424.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Preventive Effect of Korean Red Ginseng for Acute Respiratory  Illness: A Randomized and Double-Blind Clinical Trial  Korean Red Ginseng (KRG) is a functional food and has been well known for keeping good  health due to its anti-fatigue and immunomodulating activities.",Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
"http://dx.doi.org/10.3346/jkms.2012.27.12.1472   •  J Korean Med Sci 2012; 27: 1472-1478ORIGINAL ARTICLE Infectious Diseases, Microbiology & Parasitology INTRODUCTION Acute respiratory illness (ARI) is a self-limiting viral disease   that causes mild symptoms such as fever, shivering, chills, mal - aise, and dry cough.",Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
• Efficacy of Korean Red Ginseng  http://jkms.org   1473  http://dx.doi.org/10.3346/jkms.2012.27.12.1472as to increase immunoglobulin G2a in serum.,Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
• Efficacy of Korean Red Ginseng  1474   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1472at 95°C and dried under the sun or with hot air.,Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
"• Efficacy of Korean Red Ginseng  http://jkms.org   1475  http://dx.doi.org/10.3346/jkms.2012.27.12.1472RESULTS General characteristics of study subjects  After screening, a total of 100 subjects were enrolled in this study  and randomly assigned to the KRG and placebo group (male 38,  female 62).",Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
• Efficacy of Korean Red Ginseng  1476   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1472dence of NSAIDs usage between the two groups were not found  to be statistically significant.,OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
• Efficacy of Korean Red Ginseng  http://jkms.org   1477  http://dx.doi.org/10.3346/jkms.2012.27.12.1472Table 5.,Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
• Efficacy of Korean Red Ginseng  1478   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1472one of the most well studied herbal medicines.,Non-OADS,/arxiv_data1/oa_pdf/5e/79/jkms-27-1472.PMC3524425.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Candidates for Tumor Markers of Cervical Cancer Discovered by  Proteomic Analysis  Cervical cancer is the second most common gynecological cancer among Korean women.",Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
"Key Words:  Cervical Cancer; Two-Dimensional Polyacrylamide Gel Electrophoresis; Matrix  Assisted Laser Desorption/Ionization-Time of Flight Mass SpectrometryJae Yun Song1, Hyo Sook Bae1,  Do Hyoung Koo2, Jae Kwan Lee1,  Hak Hyun Jung3, Kyu Wan Lee1,  and Nak Woo Lee1 1Department of Obstetrics and Gynecology, Korea  University College of Medicine; 2Department of  Obstetrics and Gynecology, Graduate School of  Medicine, Korea University; 3Department of  Otorhinolaryngology, Korea University College of  Medicine, Seoul, Korea  Received: 22 May 2012 Accepted: 3 October 2012 Address for Correspondence: Nak Woo Lee, MD Department of Obstetrics and Gynecology, Korea University  Ansan Hospital, 123 Jeokgeum-ro, Danwon-gu, Ansan   152-703, Korea Tel: +82.31-412-4801, Fax: +82.31-132-4202 E-mail: nwlee@korea.ac.kr This research was supported by Korea University (2012- K1220431).http://dx.doi.org/10.3346/jkms.2012.27.12.1479   •  J Korean Med Sci 2012; 27: 1479-1485ORIGINAL ARTICLE Oncology & Hematology INTRODUCTION Cervical cancer is the second most common gynecological can - cer among Korean women and accounts for 9.8% of new female  cancer cases (1).",Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
• Candidates for Tumor Markers of Cervical Cancer  1480   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1479gression of cancer.,Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
"• Candidates for Tumor Markers of Cervical Cancer  http://jkms.org   1481  http://dx.doi.org/10.3346/jkms.2012.27.12.1479ileo Electro-Optics, Sturbridge, MA, USA).",Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
"• Candidates for Tumor Markers of Cervical Cancer  1482   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1479ondary antibody, and peroxidase-conjugated avidin as a chro - mogen after allowing 1 hr for primary and secondary antibody  conjugation.",Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
• Candidates for Tumor Markers of Cervical Cancer  http://jkms.org   1483  http://dx.doi.org/10.3346/jkms.2012.27.12.1479much higher in the cervical cancer tissues than in the normal  cervical tissues at the mRNA level (Fig.,Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
• Candidates for Tumor Markers of Cervical Cancer  1484   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1479immunohistochemistry.,Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
• Candidates for Tumor Markers of Cervical Cancer  http://jkms.org   1485  http://dx.doi.org/10.3346/jkms.2012.27.12.1479REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/d8/99/jkms-27-1479.PMC3524426.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Changes in the Demographics and Prognoses of Patients with  Resected Non-Small Cell Lung Cancer: A 20-Year Experience at   a Single Institution in Korea The demographics and prognosis of non-small cell lung cancer patients have changed  during the last few decades.",Non-OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
"Key Words:  Demography; Prognosis; Change; Carcinoma; Non-Small Cell Lung CancerJin Gu Lee1, Chang Young Lee1,  Mi Kyung Bae1, Chun Sung Byun2,  Dae Joon Kim1, and Kyung Young Chung1 1Department of Thoracic and Cardiovascular  Surgery, Yonsei University College of Medicine,  Seoul; 2Department of Thoracic and Cardiovascular  Surgery, Eulji University School of Medicine, Daejeon,  Korea Received: 7 July 2012 Accepted: 22 October 2012 Address for Correspondence: Kyung Young Chung, MD Department of Thoracic and Cardiovascular Surgery,   Yonsei University College of Medicine, 250 Seongsan-ro,   Seodaemun-gu, Seoul 120-752, Korea  Tel: +82.2-2228-2140, Fax: +82.2-393-6012 E-mail: kychu@yuhs.ac This study was supported by a faculty research grant of Yonsei  University College of Medicine for 201 1 (6-201 1-0148).http://dx.doi.org/10.3346/jkms.2012.27.12.1486   •  J Korean Med Sci 2012; 27: 1486-1490ORIGINAL ARTICLE  Oncology & Hematology INTRODUCTION Lung cancer is the leading cause of cancer deaths in the West - ern world as well as in Korea (1-3).",Non-OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
• Demography and Prognosis Changes of Non-Small Cell Lung Cancer http://jkms.org   1487  http://dx.doi.org/10.3346/jkms.2012.27.12.1486excluded.,Non-OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
"• Demography and Prognosis Changes of Non-Small Cell Lung Cancer 1488   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1486time was 37.3 months (range, 0 to 261.9 months).",OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
• Demography and Prognosis Changes of Non-Small Cell Lung Cancer http://jkms.org   1489  http://dx.doi.org/10.3346/jkms.2012.27.12.1486year survival rate after resection was 42.6% according to Naruke  et al.,OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
"Available  at http://www.cancer.go.kr/ncic/cics_f/02/022/index.html [accessed on  December 30, 2011].",Non-OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
• Demography and Prognosis Changes of Non-Small Cell Lung Cancer 1490   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.14865.,Non-OADS,/arxiv_data1/oa_pdf/4e/c3/jkms-27-1486.PMC3524427.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 The Incidence of Thyroid Cancer Is Affected by the Characteristics  of a Healthcare System The aim of this study was to investigate the associations between the incidence of thyroid  cancer and the characteristics of healthcare systems in OECD countries and to demonstrate  that the increasing incidence of thyroid cancer is mainly due to overdiagnosis.",Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
"Key Words:  Thyroid Neoplasms; Overdiagnosis; Healthcare System; Public Health  ExpenditureTae-Jin Lee1, Sun Kim1, Hong-Jun Cho2,  and Jae-Ho Lee3 1Graduate School of Public Health & Institute of  Health and Environment, Seoul National University,  Seoul; 2Department of Family Medicine, University  of Ulsan College of Medicine, Seoul; 3Department of  Family Medicine, The Catholic University of Korea  College of Medicine, Seoul, Korea Received: 2 September 2012 Accepted: 22 October 2012 Address for Correspondence: Jae-Ho Lee, MD Department of Family Medicine, The Catholic University of  Korea College of Medicine, 222 Banpo-daero, Seocho-gu, Seoul  137-701, Korea Tel: +82.2-2258-6288, Fax: +82.2-2258-2907 E-mail: jaeholee@catholic.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1491   •  J Korean Med Sci 2012; 27: 1491-1498ORIGINAL ARTICLE  Oncology & Hematology INTRODUCTION During the past several decades, an increasing incidence of thy - roid cancer has been reported in many parts of the world, while  its mortality has remained stable during this period.",Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
• Overdiagnosis of Thyroid Cancer 1492   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1491thyroid cancer is an extreme case.,Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
"• Overdiagnosis of Thyroid Cancer http://jkms.org   1493  http://dx.doi.org/10.3346/jkms.2012.27.12.1491compulsory or financially encouraged, and primpay it is a dum - my indicating whether or not country i’s payment to primary  care physicians is fee-for-service.",Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
• Overdiagnosis of Thyroid Cancer 1494   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1491to normalize the distribution.,Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
"• Overdiagnosis of Thyroid Cancer http://jkms.org   1495  http://dx.doi.org/10.3346/jkms.2012.27.12.1491roid cancer for both genders, although its effect became insignif - icant for males.",Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
• Overdiagnosis of Thyroid Cancer 1496   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1491respectively (unpublished observations).,Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
"• Overdiagnosis of Thyroid Cancer http://jkms.org   1497  http://dx.doi.org/10.3346/jkms.2012.27.12.1491 Meanwhile, unlike the incidence of thyroid cancer, incidenc - es of other cancers and mortality of thyroid cancer have no sig - nificant associations with the share of public health expenditure  in our analysis.",Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
Available at http://www.cancer.go.kr/ncic/index.html [accessed  on 7 August 2011].,Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
• Overdiagnosis of Thyroid Cancer 1498   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1491come of patients with differentiated thyroid carcinoma.,Non-OADS,/arxiv_data1/oa_pdf/b8/79/jkms-27-1491.PMC3524428.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Acute and Long-Term Angiographic Outcomes of Side Branch  Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-,  and Paclitaxel-Eluting Stent for Coronary Artery Stenosis This was designed to assess the outcomes of side branch (SB) stenosis after implantation of  three drug-eluting stents (DES).",Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
"Key Words:  Drug-Eluting Stents; Bifurcation; Percutaneous Coronary Intervention;     Zotarolimus; Sirolimus; PaclitaxelBong-Ki Lee1, Young-Hak Kim2,  Duk-Woo Park2, Sung-Cheol Yun3,  Jung-Min Ahn2, Hae Geun Song2,  Jong-Young Lee2, Won-Jang Kim2,  Soo-Jin Kang2, Seung-Whan Lee2,  Cheol Whan Lee2, Jae-Hwan Lee4,  In-Whan Seong4, Seong-Wook Park2,  and Seung-Jung Park2 1Division of Cardiology, Department of Internal  Medicine, Kangwon National University School of  Medicine, Kangwon National University Hospital,  Chuncheon; 2Department of Cardiology, University  of Ulsan College of Medicine, Asan Medical Center,  Seoul; 3Division of Biostatistics, Center for Medical  Research and Information, University of Ulsan  College of Medicine, Asan Medical Center, Seoul;  4Department of Cardiology, Chungnam National  University Hospital, Daejeon, Korea Received: 5 May 2012 Accepted: 1 1 October 2012 Address for Correspondence: Seung-Jung Park, MD Department of Cardiology, University of Ulsan College of  Medicine, Asan Medical Center, 88 Olympic-ro 43-gil,   Songpa-gu, Seoul 138-736, Korea Tel: +82.2-3010-4812, Fax: +82.2-475-6898 E-mail: sjpark@amc.seoul.kr This study was supported by funds from the CardioVascular  Research Foundation, Seoul, Korea, and Medtronic Vascular,  Santa Rosa, California.http://dx.doi.org/10.3346/jkms.2012.27.12.1499   •  J Korean Med Sci 2012; 27: 1499-1506ORIGINAL ARTICLE  Cardiovascular Disorders INTRODUCTION  Although the use of drug-eluting stent (DES) has improved the  outcomes of percutaneous coronary intervention (PCI), proce - dures for treatment of bifurcation lesions remain challenging  because of their technical complexity and unpredictable com - plications (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
"• Side Branches after Stenting with Drug-Eluting Stents 1500   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1499MATERIALS AND METHODS Study populations This study was a bifurcation substudy, which had been prespec - ified in the protocol of the ZEST trial.",Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
"• Side Branches after Stenting with Drug-Eluting Stents http://jkms.org   1501  http://dx.doi.org/10.3346/jkms.2012.27.12.1499the model used 15 covariates: age; gender; symptom presenta - tion; diabetes mellitus; chronic renal failure; hypercholesterol -emia; MB stent length; MB stenosis at baseline, post-procedure  and follow-up; MB in-stent late loss; SB size group; and SB ste - Table 1.",Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
• Side Branches after Stenting with Drug-Eluting Stents 1502   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1499nosis group at baseline and post-procedure.,Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
• Side Branches after Stenting with Drug-Eluting Stents http://jkms.org   1503  http://dx.doi.org/10.3346/jkms.2012.27.12.1499lower in the SES than in the ZES or PES groups.,Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
"• Side Branches after Stenting with Drug-Eluting Stents 1504   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1499 When the degree of SB diameter stenosis was classified into  four groups (< 50%, 50%-70%, 70%-99%, and 100%), worsening  of SB stenosis occurred in 48 (9.0%) of lesions comprising 21  (11.6 %), 8 (4.7%), and 19 (10.4%) lesions of the ZES, SES and  PES lesions ( P= 0.059), respectively (Fig.",Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
• Side Branches after Stenting with Drug-Eluting Stents http://jkms.org   1505  http://dx.doi.org/10.3346/jkms.2012.27.12.1499practice.,Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
• Side Branches after Stenting with Drug-Eluting Stents 1506   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1499ic stenosis and flow impairment detected by fractional flow re - serve is low (7).,Non-OADS,/arxiv_data1/oa_pdf/36/dc/jkms-27-1499.PMC3524429.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Effect of Small Hairpin RNA Targeting Endothelin-Converting  Enzyme-1 in Monocrotaline-Induced Pulmonary Hypertensive  Rats  The purpose of this study was to investigate the therapeutic effects of small hairpin RNA  (shRNA) targeting endothelin-converting enzyme (ECE) -1 in monocrotaline (MCT)-induced  pulmonary hypertensive rats.",Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
"Received: 29 May 2012 Accepted: 31 October 2012 Address for Correspondence: Young Mi Hong, MD Department of Pediatrics, Ewha Womans University School of  Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul   158-710, Korea Tel: +82.2-2650-2841, Fax: +82.2-2653-3718  E-mail: hongym@chollian.net This research was supported by grants of the Korean Society of  Pediatric Cardiology (2010-1716-001) and the Basic Science  Research Program through the National Research Foundation of  Korea funded by the Ministry of Education Science and  Technology (KRF- 2009-0064784).http://dx.doi.org/10.3346/jkms.2012.27.12.1507   •  J Korean Med Sci 2012; 27: 1507-1516ORIGINAL ARTICLE   Cardiovascular Disorders INTRODUCTION Pulmonary arterial hypertension (PAH), which is characterized  by a progressive increase in pulmonary vascular resistance lead - ing to right ventricular hypertrophy, right ventricular failure and  death, is a devastating disease with a progressive course and  poor prognosis (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
"•  Effect of RNA Interference in Pulmonary Hypertensive Rats 1508   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1507tory states, viral and hematological diseases, cancers and ge - netic disorders due to a dominant genetic effect, such as amyo - trophic lateral sclerosis (4).",Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
•  Effect of RNA Interference in Pulmonary Hypertensive Rats http://jkms.org   1509  http://dx.doi.org/10.3346/jkms.2012.27.12.1507mL and 2.0 × 107/mL were calculated respectively under fluo - rescence microscope installing a digital camera system.,OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
"•  Effect of RNA Interference in Pulmonary Hypertensive Rats 1510   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.150740% glycerol, 0.01% bromophenol blue, and 4% SDS, and then  boiled for 7 min.",Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
•  Effect of RNA Interference in Pulmonary Hypertensive Rats http://jkms.org   151 1  http://dx.doi.org/10.3346/jkms.2012.27.12.1507Histopathological examination  The MCT group showed a significant increase in medial wall  thickness on days 14 and 28.,Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
"•  Effect of RNA Interference in Pulmonary Hypertensive Rats 1512   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1507lower than those in the MCT group, but did not reach significance.",Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
"•  Effect of RNA Interference in Pulmonary Hypertensive Rats http://jkms.org   1513  http://dx.doi.org/10.3346/jkms.2012.27.12.1507Western blot analysis The protein levels of ECE-1, ET-1, ET A, TNF-α, interleukin (IL)-6,  caspase-3, Bcl-2, and VEGF in the lung tissues were significant - ly increased in the MCT group in weeks 2 and 4.",Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
•  Effect of RNA Interference in Pulmonary Hypertensive Rats 1514   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1507tially beneficial effects of ECE inhibition (20).,Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
•  Effect of RNA Interference in Pulmonary Hypertensive Rats http://jkms.org   1515  http://dx.doi.org/10.3346/jkms.2012.27.12.1507investigate the off-target effect of shRNA targeting ECE-1 injec - tion.,Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
•  Effect of RNA Interference in Pulmonary Hypertensive Rats 1516   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.150728.,Non-OADS,/arxiv_data1/oa_pdf/99/8d/jkms-27-1507.PMC3524430.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Posterior Body Surface Potential Mapping Using Capacitive- Coupled Electrodes and Its Application Using 49 capacitive-coupled electrodes, mattress-type harness was developed to obtain  posterior body surface potential map (P-BSPM) in dressed individuals.",Non-OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
201 1-0020973).http://dx.doi.org/10.3346/jkms.2012.27.12.1517   •  J Korean Med Sci 2012; 27: 1517-1523ORIGINAL ARTICLE Cardiovascular Disorders INTRODUCTION The 12-lead electrocardiogram (ECG) is a fundamental and an  important measure to examine electrical activity and diagnose  coronary heart disease.,Non-OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
"• Usefulness of Posterior Body Surface Potential Mapping 1518   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1517upper limit of normal, or 3) new ECG changes compatible with  MI.",Non-OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
• Usefulness of Posterior Body Surface Potential Mapping http://jkms.org   1519  http://dx.doi.org/10.3346/jkms.2012.27.12.1517correlation coefficient was used to evaluate correlation between  the wave axes of 12-lead ECG and vector potentials of P-BSPM.,OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
"• Usefulness of Posterior Body Surface Potential Mapping 1520   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1517and the trace in RBBB patients demonstrated that initial strong  positivity directed toward left lower field in the pattern of clock - wise rotation, and later weak negativity slowly moved from left  upper to right side of the map (Fig.",Non-OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
"• Usefulness of Posterior Body Surface Potential Mapping http://jkms.org   1521  http://dx.doi.org/10.3346/jkms.2012.27.12.1517BSPM in discriminating OMI patients from NC group were 0.83  (95% CI, 0.70-0.97; P< 0.001), 0.72 (95% CI, 0.55-0.87; P= 0.009),  and 0.86 (95% CI, 0.73-0.99; P< 0.001) for QRS complex, ST60  integral, and T-apex-end integral, respectively (Table 3).",Non-OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
"• Usefulness of Posterior Body Surface Potential Mapping 1522   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1517QRS was better in patients with pathologic Q-wave than in pa - tients without pathologic Q-wave (pathologic Q vs no patholog - ic Q: AUC 0.94 [95% CI, 0.88-1.0] vs 0.83 [0.66-0.94]; P= 0.001).",OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
• Usefulness of Posterior Body Surface Potential Mapping http://jkms.org   1523  http://dx.doi.org/10.3346/jkms.2012.27.12.1517ness of body surface potential mapping for early identification of the in - traventricular conduction disorders in young patients with chronic kid - ney disease.,Non-OADS,/arxiv_data1/oa_pdf/a9/2e/jkms-27-1517.PMC3524431.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Comparison of Lipid-Related Ratios for Prediction of Chronic  Kidney Disease Stage 3 or More in Korean Adults Dyslipidemia is implicated in increased cardiovascular risk associated with chronic kidney  disease (CKD) and in the progression of renal damage.",Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
"Key Words:  Kidney Failure, Chronic; Dyslipidemias; Glomerular Filtration Rate  Ji-Young Kim1, Hee-Taik Kang1,  Hye-Ree Lee1, Yong-Jae Lee2,  and Jae-Yong Shim1 1Department of Family Medicine, Gangnam  Severance Hospital, Yonsei University College of  Medicine, Seoul; 2Department of Family Medicine,  Yongin Severance Hospital, Yonsei University  College of Medicine, Yongin, Korea Received: 27 June 2012 Accepted: 1 1 October 2012 Address for Correspondence: Jae-Yong Shim, MD Department of Family Medicine, Yonsei University College of  Medicine, 21 1 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea Tel: +82.2-2019-3480, Fax: +82.2-3463-3287  E-mail: hope@yuhs.achttp://dx.doi.org/10.3346/jkms.2012.27.12.1524   •  J Korean Med Sci 2012; 27: 1524-1529ORIGINAL ARTICLE   Nephrology INTRODUCTION The number of people affected by chronic kidney disease (CKD)  or who require renal replacement therapy is steadily increasing  (1).",Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
"• Lipid-Related Ratios and Chronic Kidney Disease http://jkms.org   1525  http://dx.doi.org/10.3346/jkms.2012.27.12.1524rean National Health and Nutrition Examination Survey (KNH-  ANES), a cross-sectional and nationally representative survey  that was conducted by the Korean Centers for Disease Control  and Prevention, from July, 2007 to December, 2008.",Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
"• Lipid-Related Ratios and Chronic Kidney Disease 1526   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1524RESULTS Table 1 shows characteristics of the 8,650 adult subjects (3,644  men and 5,006 women).",Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
• Lipid-Related Ratios and Chronic Kidney Disease http://jkms.org   1527  http://dx.doi.org/10.3346/jkms.2012.27.12.1524Fig.,Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
• Lipid-Related Ratios and Chronic Kidney Disease 1528   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1524were < 0.05.,Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
• Lipid-Related Ratios and Chronic Kidney Disease http://jkms.org   1529  http://dx.doi.org/10.3346/jkms.2012.27.12.1524tigating the causal relationship between lipid-related ratios and  risk of CKD are needed to evaluate the value of lipid-related ra - tio control for CKD prevention.,Non-OADS,/arxiv_data1/oa_pdf/f9/31/jkms-27-1524.PMC3524432.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Optimal Range of Triglyceride Values to Estimate Serum Low  Density Lipoprotein Cholesterol Concentration in Korean Adults:  the Korea National Health and Nutrition Examination Survey, 2009 The aims of this study were to investigate the validity of Friedewald’s formula and to  propose a range of triglyceride values over which the formula can be used without  significant error.",Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
"Key Words:  Friedewald’s Formula; Cholesterol, LDL; Validation; Triglycerides; KoreanYou-Cheol Hwang1, Hong-Yup Ahn2,  In-Kyung Jeong1, Kyu Jeung Ahn1,  and Ho Yeon Chung1 1Division of Endocrinology and Metabolism,  Department of Medicine, Kyung Hee Hospital at  Gangdong, Kyung Hee University School of  Medicine, Seoul; 2Department of Statistics, Dongguk  University-Seoul, Seoul, Korea Received: 20 June 2012 Accepted: 3 October 2012 Address for Correspondence: You-Cheol Hwang, MD Division of Endocrinology and Metabolism, Department of  Medicine, Kyung Hee University Hospital at Gangdong,   Kyung Hee University School of Medicine, 892 Dongnam-ro,  Gangdong-gu, Seoul 134-727, Korea Tel: +82.2-440-6283, Fax: +82.2-440-6296 E-mail: khmcilyong@naver.com This research was supported by a grant from the Kyung Hee  University in 201 1 (KHU-201 1 1760).http://dx.doi.org/10.3346/jkms.2012.27.12.1530   •  J Korean Med Sci 2012; 27: 1530-1535ORIGINAL ARTICLE  Endocrinology, Nutrition & Metabolism INTRODUCTION Elevated serum low density lipoprotein cholesterol (LDL-C) con - centration is known to be associated with the development of  cardiovascular disease (CVD) in observational epidemiologic  studies and interventional clinical trials (1-3).",Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
• Friedewald’s Formula and Triglyceride http://jkms.org   1531  http://dx.doi.org/10.3346/jkms.2012.27.12.1530(KNHANES)-IV conducted in 2009.,Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
"• Friedewald’s Formula and Triglyceride 1532   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1530crepancies in LDL-C concentrations and clinical or laboratory  measurements, where the discrepancies were termed “delta%”  and were determined using the equation delta%.",OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
• Friedewald’s Formula and Triglyceride http://jkms.org   1533  http://dx.doi.org/10.3346/jkms.2012.27.12.1530more likely to be diagnosed with diabetes or hypertension.,Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
"• Friedewald’s Formula and Triglyceride 1534   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1530trations, and only a small portion of the subjects show discon - cordant results between the two LDL-C concentrations.",Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
"• Friedewald’s Formula and Triglyceride http://jkms.org   1535  http://dx.doi.org/10.3346/jkms.2012.27.12.1530IV), which was conducted by the Korean Centres for Disease  Control and Prevention.",OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
Available at http://knhanes.cdc.go.kr/ 16.,Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
Available at: http://www.dtu.ox.ac.uk/homa/index [accession on 27  January 2012].,Non-OADS,/arxiv_data1/oa_pdf/11/84/jkms-27-1530.PMC3524433.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 A Functional Polymorphism in the CHRNA3  Gene and Risk of  Chronic Obstructive Pulmonary Disease in a Korean Population A genome-wide association study has identified the 15q25 region as being associated with  the risk of chronic obstructive pulmonary disease (COPD) in Caucasians.",Non-OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
A090460).http://dx.doi.org/10.3346/jkms.2012.27.12.1536   •  J Korean Med Sci 2012; 27: 1536-1540ORIGINAL ARTICLE Respiratory Diseases INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a disease  characterized by airflow limitation that is not fully reversible (1).,Non-OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
"• CHRNA3  Gene Polymorphism and COPD Risk http://jkms.org   1537  http://dx.doi.org/10.3346/jkms.2012.27.12.1536ed that among the SNPs in the CHRNA5 -CHRNA3  locus, the  rs6495309C > T in the promoter of the CHRNA3 gene affects  the binding ability of the transcriptional factor, Oct-1, resulting  in alteration of CHRNA3  expression, thereby influencing lung  cancer risk (15).",Non-OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
"• CHRNA3  Gene Polymorphism and COPD Risk 1538   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1536controls was 0.494, which was comparable with that (0.482) of  healthy Chineses (15).",OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
"• CHRNA3  Gene Polymorphism and COPD Risk http://jkms.org   1539  http://dx.doi.org/10.3346/jkms.2012.27.12.1536cous secretion (17, 18).",Non-OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
"However, none  of these four SNPs were in strong LD with the rs6495309 based  on HapMap JPT data of the public database (http://www.ncbi.",Non-OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
• CHRNA3  Gene Polymorphism and COPD Risk 1540   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1536obstructive pulmonary disease (COPD): identification of two major sus - ceptibility loci.,Non-OADS,/arxiv_data1/oa_pdf/de/b6/jkms-27-1536.PMC3524434.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Coagulopathy as a Prognostic Factor of Acute Lung Injury   in Children The coagulation cascade and inflammatory process are known to be associated with the  pathophysiology of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).",Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
"Key Words:  Acute Lung Injury; Acute Respiratory Distress Syndrome; Coagulopathy;  Prothrombin Time; Partial Thromboplastin Time; PrognosisYoung Joo Han, June Dong Park,   Jae Wook Choi, Dong In Suh,   and Young Yull Koh Department of Pediatrics, Seoul National University  College of Medicine, Seoul, Korea Received: 30 March 2012 Accepted: 13 September 2012 Address for Correspondence: June Dong Park, MD Department of Pediatrics, Seoul National University College of  Medicine, 101 Daehak-ro, Jongno-gu, Seoul 1 10-744, Korea Tel: +82.2-2072-3359, Fax: +82.2-762-3359 E-mail: jdparkmd@snu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1541   •  J Korean Med Sci 2012; 27: 1541-1546ORIGINAL ARTICLE   Pediatrics INTRODUCTION The acute lung injury (ALI) and acute respiratory distress syn - drome (ARDS) are life-threatening clinical syndromes charac - terized by severe inflammation in the lungs.",Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
"• Coagulopathy as a Prognosic Factor of Acute Lung Injury 1542   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1541alveolar pressure ×100/PaO 2) and ventilation index (9) (VI; re - spiratory rate ×([peak inspiratory pressure – positive end-expi - ratory pressure] ×PaCO 2/1,000) were used to stratify patients  into the lower and higher severity groups.",Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
"• Coagulopathy as a Prognosic Factor of Acute Lung Injury http://jkms.org   1543  http://dx.doi.org/10.3346/jkms.2012.27.12.1541antithrombin III and vitamin K after the diagnosis of ALI/ARDS  were done in 43 and 56 patients (52 and 67%), respectively.",Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
• Coagulopathy as a Prognosic Factor of Acute Lung Injury 1544   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.154129 survivors (17%) and 6 of 45 non-survivors (13%).,Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
"• Coagulopathy as a Prognosic Factor of Acute Lung Injury http://jkms.org   1545  http://dx.doi.org/10.3346/jkms.2012.27.12.1541all coagulation factors except factor VII or XIII is diminished,  which indicates the abnormality of the intrinsic pathway.",Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
"• Coagulopathy as a Prognosic Factor of Acute Lung Injury 1546   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1541driguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.",Non-OADS,/arxiv_data1/oa_pdf/ae/a9/jkms-27-1541.PMC3524435.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Infant Pertussis and Household Transmission in Korea A recent resurgence of pertussis has raised public health concerns even in developed  countries with high vaccination coverage.",Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
"5-2010-00340- 0001).http://dx.doi.org/10.3346/jkms.2012.27.12.1547   •  J Korean Med Sci 2012; 27: 1547-1551ORIGINAL ARTICLE Pediatrics INTRODUCTION Pertussis, also known as whooping cough, is an acute respira - tory tract infection caused by Bordetella pertussis .",Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
"• Pertussis Infection in Infants 1548   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1547MATERIALS AND METHODS Data sources A prospective, multicenter, observational study was conducted  between January 2009 and September 2011.",Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
"• Pertussis Infection in Infants http://jkms.org   1549  http://dx.doi.org/10.3346/jkms.2012.27.12.1547There were 4 cases (19.0%) of pneumonic infiltration, 3 cases  (14.3%) of hyperinflation on radiologic examinations.",Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
"• Pertussis Infection in Infants 1550   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1547September, which have relatively warm temperatures in Korea.",Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
• Pertussis Infection in Infants http://jkms.org   1551  http://dx.doi.org/10.3346/jkms.2012.27.12.1547in infants and children.,Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
Available at http://www.cdc.go.kr [accessed  on 12 August 2012].,Non-OADS,/arxiv_data1/oa_pdf/c3/9a/jkms-27-1547.PMC3524436.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 High Incidence of Rickets in Extremely Low Birth Weight Infants  with Severe Parenteral Nutrition-Associated Cholestasis and  Bronchopulmonary Dysplasia  Risk factors for rickets of prematurity have not been re-examined since introduction of  high mineral formula, particularly in ELBW infants.",Non-OADS,/arxiv_data1/oa_pdf/79/8b/jkms-27-1552.PMC3524437.pdf
"201 1- 0014207).http://dx.doi.org/10.3346/jkms.2012.27.12.1552   •  J Korean Med Sci 2012; 27: 1552-1555ORIGINAL ARTICLE Pediatrics INTRODUCTION In the 1980s, the prevalence of rickets in extremely low birth  weight (ELBW) infants was around 50% and was 17% for frac - tures (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/79/8b/jkms-27-1552.PMC3524437.pdf
"• High Incidence and Risk Factors of Rickets in ELBW Infants http://jkms.org   1553  http://dx.doi.org/10.3346/jkms.2012.27.12.1552and multivitamins with trace minerals were added to parenter - al nutrition, appropriately.",Non-OADS,/arxiv_data1/oa_pdf/79/8b/jkms-27-1552.PMC3524437.pdf
"• High Incidence and Risk Factors of Rickets in ELBW Infants 1554   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1552ed with severe PNAC (OR 18.5; 95% CI, 1.1-285; P= 0.042) and  moderate/severe BPD (OR 3.2; 95% CI, 1.2-26.5; P= 0.04) (Ta - ble 3).",Non-OADS,/arxiv_data1/oa_pdf/79/8b/jkms-27-1552.PMC3524437.pdf
• High Incidence and Risk Factors of Rickets in ELBW Infants http://jkms.org   1555  http://dx.doi.org/10.3346/jkms.2012.27.12.1552calcium regulation and reduces bone mineralization in infant pigs.,Non-OADS,/arxiv_data1/oa_pdf/79/8b/jkms-27-1552.PMC3524437.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Retinopathy of Prematurity in Infants Born before 25 Weeks  Gestation in a Korean Single Neonatal Intensive Care Unit:  Incidence, Natural History and Risk Factors  As younger preterm infants are able to survive, more extremely preterm infants are at risk  of developing retinopathy of prematurity (ROP).",Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
"http://dx.doi.org/10.3346/jkms.2012.27.12.1556   •  J Korean Med Sci 2012; 27: 1556-1562ORIGINAL ARTICLE Pediatrics INTRODUCTION  Retinopathy of prematurity (ROP), a disease that affects imma - ture vasculature in the eyes of premature infants, remains a ma - jor cause of blindness and visual impairment in children world - wide (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
"• Retinopathy of Prematurity in Infants Born before 25 Weeks Gestation http://jkms.org   1557  http://dx.doi.org/10.3346/jkms.2012.27.12.1556vere form of ROP characterized by its posterior location, promi - nence of plus disease, the ill-defined nature of the retinopathy,  and the rapid progression (12).",Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
• Retinopathy of Prematurity in Infants Born before 25 Weeks Gestation 1558   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1556shown in Table 1.,Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
"• Retinopathy of Prematurity in Infants Born before 25 Weeks Gestation http://jkms.org   1559  http://dx.doi.org/10.3346/jkms.2012.27.12.1556a GA of 22, 23, and 24 weeks were 36.4 ±2.4 (range, 33+0-39+2),  36.2±2.3 (range, 31+5-40+5), and 36.0 ±2.6 weeks (range, 30+2 -41+6), respectively.",Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
"• Retinopathy of Prematurity in Infants Born before 25 Weeks Gestation 1560   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1556icance (OR, 2.415; P= 0.064).",Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
"• Retinopathy of Prematurity in Infants Born before 25 Weeks Gestation http://jkms.org   1561  http://dx.doi.org/10.3346/jkms.2012.27.12.1556ROP studies, low birth weight was significantly associated with  the development of severe ROP (22-24).",Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
• Retinopathy of Prematurity in Infants Born before 25 Weeks Gestation 1562   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.155623.,Non-OADS,/arxiv_data1/oa_pdf/c0/6a/jkms-27-1556.PMC3524438.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Incidence and Risk Factors of Ventriculoperitoneal Shunt Infections  in Children: A Study of 333 Consecutive Shunts in 6 Years The major aims of this study were to estimate the infection rate and recognize the risk  factor for ventriculoperitoneal (VP) shunt infections in children.",Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
"Key Words:  Ventriculoperitoneal Shunt; Infection; Prophylaxis; ChildJoon Kee Lee1, Joon Young Seok1,  Joon Ho Lee1, Eun Hwa Choi1,  Ji Hoon Phi2, Seung-Ki Kim2,  Kyu-Chang Wang2, and Hoan Jong Lee1 1Department of Pediatrics and 2Division of Pediatric  Neurosurgery, Seoul National University Children’s  Hospital, Seoul National University College of  Medicine, Seoul, Korea Received: 27 June 2012 Accepted: 23 October 2012 Address for Correspondence: Eun Hwa Choi, MD Department of Pediatrics, Seoul National University Children’s  Hospital, Seoul National University College of Medicine,   101 Daehak-ro, Jongno-gu, Seoul 1 10-744, Korea Tel: +82.2-2072-3624, Fax: +82.2-766-7283 E-mail: eunchoi@snu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1563   •  J Korean Med Sci 2012; 27: 1563-1568ORIGINAL ARTICLE Pediatrics INTRODUCTION Hydrocephalus is caused by the inability of cerebrospinal fluid  (CSF) to drain into the bloodstream.",Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
"• Ventriculoperitoneal Shunt Infections 1564   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1563in association with positive blood culture when a patient pre - sented any of the following: fever, neurologic symptoms, abdom - inal symptoms, or shunt malfunction.",Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
• Ventriculoperitoneal Shunt Infections http://jkms.org   1565  http://dx.doi.org/10.3346/jkms.2012.27.12.1563pathogen was identified in 31 out of 35 shunt infections (88.6%).,Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
• Ventriculoperitoneal Shunt Infections 1566   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1563that had been re-inserted after a previous shunt removal.,Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
"• Ventriculoperitoneal Shunt Infections http://jkms.org   1567  http://dx.doi.org/10.3346/jkms.2012.27.12.1563tion rate of 10.3% in the 271 cases who were given with first gen - eration cephalosporin versus 11.1% in the 36 cases given with  vancomycin, P= 0.77).",Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
• Ventriculoperitoneal Shunt Infections 1568   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1563tions.,Non-OADS,/arxiv_data1/oa_pdf/a3/d6/jkms-27-1563.PMC3524439.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Application of Sperm Selection Using Hyaluronic Acid Binding in  Intracytoplasmic Sperm Injection Cycles: A Sibling Oocyte Study  The purpose of this study was to investigate whether sperm selection by hyaluronic acid  (HA) binding could improve fertilization rate and embryo quality in intracytoplasmic sperm  injection (ICSI) cycles.",Non-OADS,/arxiv_data1/oa_pdf/f8/c4/jkms-27-1569.PMC3524440.pdf
"02-201 1-007).http://dx.doi.org/10.3346/jkms.2012.27.12.1569   •  J Korean Med Sci 2012; 27: 1569-1573ORIGINAL ARTICLE  Obstetrics & Gynecology INTRODUCTION Although various techniques have rapidly been developed over  30 yr in the field of assisted reproduction, the success rate re - mains low (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/f8/c4/jkms-27-1569.PMC3524440.pdf
• Hyaluronic Acid Binding in Intracytoplasmic Sperm Injection  Cycles 1570   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1569sent form.,Non-OADS,/arxiv_data1/oa_pdf/f8/c4/jkms-27-1569.PMC3524440.pdf
• Hyaluronic Acid Binding in Intracytoplasmic Sperm Injection  Cycles http://jkms.org   1571  http://dx.doi.org/10.3346/jkms.2012.27.12.1569and gave their written informed consents.,Non-OADS,/arxiv_data1/oa_pdf/f8/c4/jkms-27-1569.PMC3524440.pdf
• Hyaluronic Acid Binding in Intracytoplasmic Sperm Injection  Cycles 1572   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1569ence of history of RIF between the pregnancy group and non- pregnancy group (data not shown).,Non-OADS,/arxiv_data1/oa_pdf/f8/c4/jkms-27-1569.PMC3524440.pdf
• Hyaluronic Acid Binding in Intracytoplasmic Sperm Injection  Cycles http://jkms.org   1573  http://dx.doi.org/10.3346/jkms.2012.27.12.156913.,Non-OADS,/arxiv_data1/oa_pdf/f8/c4/jkms-27-1569.PMC3524440.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Ocular Surface Discomfort and Demodex : Effect of Tea Tree Oil  Eyelid Scrub in Demodex  Blepharitis The purpose of this study was to evaluate the relation between ocular discomfort and  ocular Demodex  infestation, and therapeutic effects of tea tree oil (TTO) in Demodex   blepharitis patients.",Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
"http://dx.doi.org/10.3346/jkms.2012.27.12.1574   •  J Korean Med Sci 2012; 27: 1574-1579ORIGINAL ARTICLE Ophthalmology INTRODUCTION Demodex  (class Arachnida , superorder Acariformes ) is one of  the most commonly found ectoparasites in humans (1).",Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
"• Ocular Discomfort in Demodex  blepharitis and Tea Tree Oil Treatment http://jkms.org   1575  http://dx.doi.org/10.3346/jkms.2012.27.12.1574Study participants Three hundred and thirty five patients with ocular surface dis - comfort, such as dryness, pruritus, ocular pain, or visual distur - bance were enrolled between October 1, 2009 and December  31, 2011.",Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
"• Ocular Discomfort in Demodex  blepharitis and Tea Tree Oil Treatment 1576   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1574RESULTS Demographic and clinical features The 335 patients enrolled in this study included 104 men and  231 women, with an average age of 55.7 ±12.4 yr (range, 23-85  yr).",Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
• Ocular Discomfort in Demodex  blepharitis and Tea Tree Oil Treatment http://jkms.org   1577  http://dx.doi.org/10.3346/jkms.2012.27.12.1574moderate group showed 18.9% eradication rate.,Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
"• Ocular Discomfort in Demodex  blepharitis and Tea Tree Oil Treatment 1578   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1574score of patients with ocular Demodex  was 20.1, which indicates  moderate to severe ocular discomfort.",Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
• Ocular Discomfort in Demodex  blepharitis and Tea Tree Oil Treatment http://jkms.org   1579  http://dx.doi.org/10.3346/jkms.2012.27.12.1574Soc 1967; 65: 361-92.,Non-OADS,/arxiv_data1/oa_pdf/67/c5/jkms-27-1574.PMC3524441.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Comparison of Systemic Adverse Events Associated with  Intravitreal Anti-VEGF Injection: Ranibizumab versus  Bevacizumab The aim of this study was to compare the incidence of systemic adverse events in patients  treated with intravitreal injections of bevacizumab or ranibizumab, and to evaluate  whether compared to ranibizumab administration, bevacizumab constitutes a higher risk  for systemic adverse events.",Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
"Key Words:  Adverse Drug Event; Bevacizumab; Intravitreal Injections; RanibizumabDuck Jin Hwang1, Yong Woo Kim2,  Se Joon Woo1, and Kyu Hyung Park1 Department of Ophthalmology, Seoul National  University College of Medicine, 1Seoul National  University Bundang Hospital, Seongnam; 2Seoul  National University Hospital, Seoul, Korea Received: 26 July 2012 Accepted: 20 September 2012 Address for Correspondence: Kyu Hyung Park, MD Department of Ophthalmology, Seoul National University  Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu,  Seongnam 463-707, Korea Tel: +82.31-787-7373, Fax: +82.31-787-4057 E-mail: jiani4@snu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1580   •  J Korean Med Sci 2012; 27: 1580-1585ORIGINAL ARTICLE  Ophthalmology INTRODUCTION The use of intravitreal injection of anti-vascular endothelial  growth factor (anti-VEGF) agents has increased dramatically  over the course of 5 yr and has become part of everyday praxis.",Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
• Systemic Adverse Events of Anti-VEGF http://jkms.org   1581  http://dx.doi.org/10.3346/jkms.2012.27.12.1580for systemic adverse events than does ranibizumab injection.,Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
• Systemic Adverse Events of Anti-VEGF 1582   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1580servation period ( P< 0.001).,Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
• Systemic Adverse Events of Anti-VEGF http://jkms.org   1583  http://dx.doi.org/10.3346/jkms.2012.27.12.1580vein occlusion (0.5%).,Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
• Systemic Adverse Events of Anti-VEGF 1584   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1580ti-VEGF molecule absorption (9).,Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
"• Systemic Adverse Events of Anti-VEGF http://jkms.org   1585  http://dx.doi.org/10.3346/jkms.2012.27.12.1580predictors were mostly classified in a binary fashion (e.g., dia - betes mellitus: yes or no or hypertension: yes or no) rather than  in more detail (e.g.",Non-OADS,/arxiv_data1/oa_pdf/f4/0d/jkms-27-1580.PMC3524442.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Reciprocal Deletion and Duplication of 17p11.2-11.2: Korean  Patients with Smith-Magenis Syndrome and Potocki-Lupski  Syndrome  Deletion and duplication of the -3.7-Mb region in 17p1 1.2 result in two reciprocal  syndrome, Smith-Magenis syndrome and Potocki-Lupski syndrome.",Non-OADS,/arxiv_data1/oa_pdf/b8/29/jkms-27-1586.PMC3524443.pdf
"Key Words:  Array-CGH; 17p1 1.2; Deletion; Duplication; Potocki-Lupski Syndrome (PTLS);  Smith-Magenis Syndrome (SMS) Cha Gon Lee1, Sang-Jin Park2,  Jun-No Yun3, Shin-Young Yim4,  and Young Bae Sohn3 1Department of Pediatrics, Eulji General Hospital,  Seoul; 2MG MED, Inc., Seoul; 3Department of  Medical Genetics, 4Department of Physical Medicine  and Rehabilitation, Ajou University School of  Medicine, Suwon, Korea Received: 4 June 2012 Accepted: 14 August 2012 Address for Correspondence: Young Bae Sohn, MD Department of Medical Genetics, Ajou University School of  Medicine, 164 World cup-ro, Yeongtong-gu, Suwon   443-721, Korea  Tel: +82.31-219-4522, Fax: +82.31-219-4521 E-mail: ybsohn@ajou.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1586   •  J Korean Med Sci 2012; 27: 1586-1590CASE REPORT Human Genetics & Genomics INTRODUCTION A number of common contiguous gene syndromes arise from   a nonallelic homologous recombination mechanism.",Non-OADS,/arxiv_data1/oa_pdf/b8/29/jkms-27-1586.PMC3524443.pdf
"• Reciprocal Deletion and Duplication of 17p1 1.2-1 1.2 http://jkms.org   1587  http://dx.doi.org/10.3346/jkms.2012.27.12.1586cm (-1.16 SDS), body mass index (BMI) was 15.96 kg/m2 (-0.62  SDS), and head circumference was 50 cm (-1.19 SDS).",OADS,/arxiv_data1/oa_pdf/b8/29/jkms-27-1586.PMC3524443.pdf
"• Reciprocal Deletion and Duplication of 17p1 1.2-1 1.2 1588   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1586MIR33B  [MIM 613486], TOM1L2 , TRIM16L , FBXW10  [MIM  611679], FAM18B , ALDH3A2  [MIM 609523], SLC47A  [MIM 60 - 9833], and ALDH3A1  [MIM 100660].",Non-OADS,/arxiv_data1/oa_pdf/b8/29/jkms-27-1586.PMC3524443.pdf
"• Reciprocal Deletion and Duplication of 17p1 1.2-1 1.2 http://jkms.org   1589  http://dx.doi.org/10.3346/jkms.2012.27.12.1586disturbance, obesity, and craniofacial/skeletal anomalies.",Non-OADS,/arxiv_data1/oa_pdf/b8/29/jkms-27-1586.PMC3524443.pdf
• Reciprocal Deletion and Duplication of 17p1 1.2-1 1.2 1590   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.15866.,Non-OADS,/arxiv_data1/oa_pdf/b8/29/jkms-27-1586.PMC3524443.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Cauda Equina Syndrome Caused by Pseudogout Involving the  Lumbar Intervertebral Disc Calcium pyrophosphate dihydrate (CPPD) deposition disease, also known as pseudogout, is  a disease that causes inflammatory arthropathy in peripheral joints, however, symptomatic  involvement of the intervertebral disc is uncommon.",Non-OADS,/arxiv_data1/oa_pdf/37/04/jkms-27-1591.PMC3524444.pdf
"Key Words:  Calcium Pyrophosphate Dehydrate (CPPD); Pseudogout; Lumbar Spine;  Intervertebral DiscJungjun Lee1, Keun-Tae Cho1,  and Eo-Jin Kim2 Departments of 1Neurosurgery and 2Pathology,  Dongguk University Ilsan Hospital, Goyang, Korea Received: 7 April 2012 Accepted: 27 August 2012 Address for Correspondence: Keun-Tae Cho, MD Department of Neurosurgery, Dongguk University Ilsan Hospital,  27 Donggung-ro, Ilsandong-gu, Goyang 410-773, Korea Tel: +82.31-961-7322, Fax: +82.31-961-7327 E-mail: ktcho21@naver.comhttp://dx.doi.org/10.3346/jkms.2012.27.12.1591   •  J Korean Med Sci 2012; 27: 1591-1594CASE REPORT Immunology, Allergic Disorders & Rheumatology INTRODUCTION Calcium pyrophosphate dihydrate (CPPD) deposition disease  is defined as the deposition of CPPD crystals in the articular or  periarticular structures that leads to inflammation of the joints  (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/37/04/jkms-27-1591.PMC3524444.pdf
• Pseudogout Involving the Lumbar Intervertebral Disc  1592   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1591thecal sac.,Non-OADS,/arxiv_data1/oa_pdf/37/04/jkms-27-1591.PMC3524444.pdf
• Pseudogout Involving the Lumbar Intervertebral Disc  http://jkms.org   1593  http://dx.doi.org/10.3346/jkms.2012.27.12.1591CPPD deposition was found in 4 patients with degenerated disc  (9).,Non-OADS,/arxiv_data1/oa_pdf/37/04/jkms-27-1591.PMC3524444.pdf
• Pseudogout Involving the Lumbar Intervertebral Disc  1594   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1591to calcium pyrophosphate crystal deposition (pseudogout).,Non-OADS,/arxiv_data1/oa_pdf/37/04/jkms-27-1591.PMC3524444.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Thoracoscopic Left Ventricular Lead Implantation in Cardiac  Resynchronization Therapy Cardiac resynchronization therapy is known to reduce morbidity and mortality in patients  with advanced heart failure as a result of dyssynchrony and systolic dysfunction of the left  ventricle.",Non-OADS,/arxiv_data1/oa_pdf/7b/7f/jkms-27-1595.PMC3524445.pdf
"Key Words:  Cardiac Resynchronization Therapy; ThoracoscopyDong Seop Jeong1, Pyo Won Park1,  Young Tak Lee1, Seung-Jung Park2,  June Soo Kim2, and Young Keun On2 1Department of Thoracic and Cardiovascular  Surgery, 2Division of Cardiology, Department of  Medicine, Samsung Medical Center, Sungkyunkwan  University School of Medicine, Seoul, Korea Received: 14 May 2012 Accepted: 1 1 October 2012 Address for Correspondence: Young Keun On, MD Division of Cardiology, Department of Medicine, Samsung  Medical Center, Sungkyunkwan University School of Medicine,  81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea Tel: +82.2-3410-1278, Fax: +82.2-3410-0089 E-mail: cabg@korea.comhttp://dx.doi.org/10.3346/jkms.2012.27.12.1595   •  J Korean Med Sci 2012; 27: 1595-1597CASE REPORT Cardiovascular Disorders INTRODUCTION The incidence of chronic heart failure is increasing due to an ag - ing population, and approximately 30% of patients with heart  failure develop conduction disturbance such as atrioventricular  (AV) block or left bundle branch block (1-4).",Non-OADS,/arxiv_data1/oa_pdf/7b/7f/jkms-27-1595.PMC3524445.pdf
• Thoracoscopic Left Ventricular Lead Implantation 1596   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1595 The operation was performed under general anesthesia us - ing a double lumen tube for unilateral lung ventilation.,Non-OADS,/arxiv_data1/oa_pdf/7b/7f/jkms-27-1595.PMC3524445.pdf
• Thoracoscopic Left Ventricular Lead Implantation http://jkms.org   1597  http://dx.doi.org/10.3346/jkms.2012.27.12.1595changes in pacing thresholds.,Non-OADS,/arxiv_data1/oa_pdf/7b/7f/jkms-27-1595.PMC3524445.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Spontaneous Bacterial Peritonitis with Sepsis Caused by  Enterococcus hirae Selective intestinal decontamination (SID) with norfloxacin has been widely used for the  prophylaxis of spontaneous bacterial peritonitis (SBP) because of a high recurrence rate  and preventive effect of SID for SBP.",Non-OADS,/arxiv_data1/oa_pdf/b8/1c/jkms-27-1598.PMC3524446.pdf
"Key Words:  Enterococcus hirae ; Spontaneous Bacterial Peritonitis; Sepsis; Liver CirrhosisJong Seop Sim, Hyoung Su Kim,   Ki Jong Oh, Myung Soo Park,   Eun Ju Jung, Youn Joo Jung,   Dae Gil Kang, Seung In Seo, Won Jin Kim,  and Myoung Kuk Jang Department of Internal Medicine, Kangdong Sacred  Heart Hospital of Hallym University Medical Center,  Seoul, Korea Received: 1 1 June 2012 Accepted: 14 August 2012 Address for Correspondence: Hyoung Su Kim, MD Department of Internal Medicine, Kangdong Sacred Heart  Hospital, University of Hallym College of Medicine,   150 Seongan-ro, Gangdong-gu, Seoul 134-701, Korea Tel: +82.2-2225-2889, Fax: +82.2-478-6925 E-mail: hskim@hallym.or.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1598   •  J Korean Med Sci 2012; 27: 1598-1600CASE REPORT Gastroenterology & Hepatology INTRODUCTION Spontaneous bacterial peritonitis (SBP) is the most common  infection with a high morbidity and mortality, occurring in 10%  to 30% of cirrhotic patients with ascites, and associated with a  very high rate of recurrence (1).",Non-OADS,/arxiv_data1/oa_pdf/b8/1c/jkms-27-1598.PMC3524446.pdf
• Enterococcus hirae  Spontaneous Bacterial Peritonitis http://jkms.org   1599  http://dx.doi.org/10.3346/jkms.2012.27.12.1598rum creatinine 1.7 mg/dL.,Non-OADS,/arxiv_data1/oa_pdf/b8/1c/jkms-27-1598.PMC3524446.pdf
• Enterococcus hirae  Spontaneous Bacterial Peritonitis 1600   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1598concern in prophylaxis of SBP in cirrhotic patients.,Non-OADS,/arxiv_data1/oa_pdf/b8/1c/jkms-27-1598.PMC3524446.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Leukocytoclastic Vasculitis Associated with Influenza A Virus  Infection Leukocytoclastic vasculitis (LCV) usually presents palpable purpura characterized by  inflammation of vessel walls and fragmentation of nuclei.",Non-OADS,/arxiv_data1/oa_pdf/da/c9/jkms-27-1601.PMC3524447.pdf
"Key Words:  Leukocytoclastic Vasculitis; Influenza A Virus InfectionHyo Jin Lee, Dong Hoon Shin,   Jong Soo Choi, and Ki Hong Kim Department of Dermatology, Yeungnam University  College of Medicine, Daegu, Korea Received: 1 1 June 2012 Accepted: 30 July 2012 Address for Correspondence: Dong Hoon Shin, MD Department of Dermatology, Yeungnam University College of  Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu 705-802, Korea Tel: +82.53-620-3160, Fax: +82.53-622-2216 E-mail: dhshin@med.yu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1601   •  J Korean Med Sci 2012; 27: 1601-1603CASE REPORT Dermatology INTRODUCTION Influenza A virus infection may present various clinical mani - festation.",Non-OADS,/arxiv_data1/oa_pdf/da/c9/jkms-27-1601.PMC3524447.pdf
"• Leukocytoclastic Vasculitis with Influenza A Virus 1602   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1601pected and prednisolone (4 mg three times a day, orally) and  cephalosporin (450 mg twice a day, intravenously) were admin - istered.",Non-OADS,/arxiv_data1/oa_pdf/da/c9/jkms-27-1601.PMC3524447.pdf
"• Leukocytoclastic Vasculitis with Influenza A Virus http://jkms.org   1603  http://dx.doi.org/10.3346/jkms.2012.27.12.1601sions can be uncommonly observed (8, 9).",Non-OADS,/arxiv_data1/oa_pdf/da/c9/jkms-27-1601.PMC3524447.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Recalcitrant Cutaneous Ulcer of Comorbid Patient Treated with  Platelet Rich Plasma: A Case Report The platelet-rich plasma (PRP) has been advocated as a way to introduce increased  concentrations of growth factors and other bioactive molecules to injured tissues in an  attempt to optimize the local healing environment.",Non-OADS,/arxiv_data1/oa_pdf/8f/f6/jkms-27-1604.PMC3524448.pdf
"Key Words:  Platelet Rich Plasma (PRP); Refractory Ulcer; Aged; DiabetesDai Hyun Kim, Jong Yeob Kim,   Soo Hong Seo, Hyo Hyun Ahn,   Young Chul Kye, and Jae Eun Choi Department of Dermatology, Korea University  College of Medicine, Seoul, Korea Received: 10 June 2012 Accepted: 22 August 2012 Address for Correspondence: Jae Eun Choi, MD Department of Dermatology, Korea University College of  Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea  Tel: +82.2-920-5470, Fax: +82.2-928-7540 E-mail: grace79@korea.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.12.1604   •  J Korean Med Sci 2012; 27: 1604-1606CASE REPORT Dermatology INTRODUCTION In recent years the problem of “cutaneous ulcers” (venous, ar - terial, diabetic, and pressure sores) has become increasingly  important, in particular because of the progressive increase in  the elderly population and, therefore, of chronic disorders (1).",Non-OADS,/arxiv_data1/oa_pdf/8f/f6/jkms-27-1604.PMC3524448.pdf
• Recalcitrant Cutaneous Ulcer Treated with Platelet Rich Plasma http://jkms.org   1605  http://dx.doi.org/10.3346/jkms.2012.27.12.1604treatments involved topically application of activated PRP as  well as packing of the wound with aseptic film for the sustained  effect of growth factors.,Non-OADS,/arxiv_data1/oa_pdf/8f/f6/jkms-27-1604.PMC3524448.pdf
"• Recalcitrant Cutaneous Ulcer Treated with Platelet Rich Plasma 1606   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.12.1604efficacy, and safety of autologous PRP therapy, it could be con - sidered as an effective alternative option for the recalcitrant cu - taneous ulcer with various comorbidities.",Non-OADS,/arxiv_data1/oa_pdf/8f/f6/jkms-27-1604.PMC3524448.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 CORRESPONDENCE Erratum: Correction of Misspelling of Title and Author Affiliation Ki Young Son1, Cheol Min Lee2, BeLong Cho1, Youl Lee Lym3, Seung Won Oh2, Wonjoo Chung1, Jin-Seok Lee4, DuShin Park5,  and Han Suk Kim6 1Department of Family Medicine, Seoul National University Hospital, Seoul; 2Department of Family Medicine, Healthcare System Gangnam Centre,  Seoul National University Hospital, Seoul; 3Department of Family Medicine, Konkuk University Hospital, Seoul; 4Department of Health Policy and Management,  Seoul National University College of Medicine, Seoul; 5National Health Insurance Corporation, Seoul; 6Ministry for Health and Welfare, Seoul, Korea To the Editor: We found two errors in our published article:   Ki Young  Son, Cheol  Min Lee, BeLong  Cho, Youl Lee Lym,  Seung  Won Oh, Wonjoo  Chung,  Jin-Seok  Lee, DuShin  Park,  and Han  Suk Kim.",Non-OADS,/arxiv_data1/oa_pdf/ab/8d/jkms-27-1607.PMC3524449.pdf
"Effect  of Additional  Brief Counselling  after Periodic  Health  Examination    on Motivation  for Health  Behavior  Change   Ki Young Son1,*, Cheol Min Lee2,*, BeLong Cho1, Youl Lee Lym3, Seung Won Oh2, Wonjoo Chung1, Jin-Seok Lee4,  DuShin Park5, and Han Suk Kim6  1Department of Family Medicine, Seoul National University Hospital, Seoul; 2Department of Family Medicine, Healthcare System Gangnam Centre,  Seoul National University Hospital, Seoul; 3Department of Family Medicine, Konkuk University Hospital, Seoul; 4Department of Health Policy and Management,  Seoul National University College of Medicine, Seoul; 5National Health Insurance Corporation, Seoul; 6Ministry for Health and Welfare, Seoul, Koreahttp://dx.doi.org/10.3346/jkms.2012.27.12.1607   •  J Korean Med Sci 2012; 27: 1607",Non-OADS,/arxiv_data1/oa_pdf/ab/8d/jkms-27-1607.PMC3524449.pdf
"Copyright © 2012 The Korean Society of Environmental Health and T oxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6 EHThttp://e-eht.org/Need for Development of Policy and  Techniques Addressing Health Impacts   of Climate-change According to the fourth report of the United Nations Intergov - ernmental Panel on Climate Change (IPCC), global average  temperatures have increased over the past 100 years by 0.74 ˚C,  with a total predicted rise of 6.4 ˚C by the century’s end [1].",Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
"Keywords  Climate change, Health impacts, Policy directions Correspondence:  Jongsik Ha, PhD 215 Jinheung-ro, Eunpyeong-gu,   Seoul 122-706, Korea T el: +82-2-380-7754 Fax: +82-2-380-7644 E-mail: jsha@kei.re.kr Received:  June 10, 2012 Accepted:  August 31, 2012 Published online:  November 30, 2012 This article is available from: http:// e-eht.org/Volume: 27, Article ID: e2012018, 6 pages   http://dx.doi.org/10.5620/eht.2012.27.e2012018  EHTEnvironmental Health and Toxicology eISSN: 2233-6567 •  Special  Topic  Open Access",Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
"Page 2 of 6Environmental Health and Toxicology    2012;27:e2012018 EHT http://e-eht.org/heat waves that have claimed the lives of 2,127 people between  1994 and 2005 [4].",Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
YS Shin and J Ha  | Policy Directions Addressing Public Health Impact of Climate Change Page 3 of 6  EHThttp://e-eht.org/Table 1.,Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
Page 4 of 6Environmental Health and Toxicology    2012;27:e2012018 EHT http://e-eht.org/change adaptation measures (2011-2015) along with the chal - lenges faced by each relevant ministry [9].,Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
YS Shin and J Ha  | Policy Directions Addressing Public Health Impact of Climate Change Page 5 of 6  EHThttp://e-eht.org/database by the end of 2011.,Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
"Page 6 of 6Environmental Health and Toxicology    2012;27:e2012018 EHT http://e-eht.org/Acknowledgements This study was supported by the “Development of Climate- change Health Impact Assessment and Adaptation T echnolo - gies” project of the Korea Environment Institute, funded by Eco- innovation, the Ministry of the Environment, Korea (# 412- 111-001) and by the “Policy Direction for Assessment and Ad - aptation in Health Impact of Climate Change” project of the  Korea Environment Institute (# WO-2011-01).",Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
Available from: http://www.who.int/quantifying_ehimpacts/ summaryEBD_updated.pdf.,OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
Available from:  http://www.ipcc.ch/activities/activities.shtml.,Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
Available from: http://www.ftsnet.it/docu - menti/162/Health%20Effects%20of%20climate%20change%20 in%20the%20UK%202008.pdf.,Non-OADS,/arxiv_data1/oa_pdf/78/2b/eht-27-e2012018.PMC3524451.pdf
"Copyright © 2012 The Korean Society of Environmental Health and T oxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7 EHThttp://e-eht.org/Introduction Asthma is one of the most common chronic diseases in child - hood and imposes a substantial socioeconomic burden [1].",Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
"Keywords  Asthma, Children, Income, Interaction, Sibling effectCorrespondence: Hojang Kwon, PhD 119 Dandae-ro, Dongnam-gu,  Cheonan 330-714, Korea T el: +82-41-550-3879 Fax: +82-41-556-6461 E-mail: hojang@dankook.ac.kr Received:  August 29, 2012 Accepted:  October 30, 2012 Published online:  November 30, 2012 This article is available from: http:// e-eht.org/Volume: 27, Article ID: e2012020, 7 pages   http://dx.doi.org/10.5620/eht.2012.27.e2012020  EHTEnvironmental Health and Toxicology eISSN: 2233-6567 •  Original  ArticleOpen Access",Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
Page 2 of 7Environmental Health and Toxicology    2012;27:e2012020 EHT http://e-eht.org/against allergic diseases.,Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
"Questionnaire Survey  A web-based survey was conducted from June to October,  2009, via the Seoul Asthma Atopy Education Information Cen - ter website (http://www.atopyinfocenter.co.kr).",Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
| Household Income and Childhood Asthma Page 3 of 7  EHThttp://e-eht.org/million won.,Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
"Page 4 of 7Environmental Health and Toxicology    2012;27:e2012020 EHT http://e-eht.org/tively associated with boys ( p<0.01), parental history of asthma  (p<0.01), smoking in the household ( p<0.01), living in base - ments ( p=0.03), and moving to a new house within the first  year of a child’s life ( p<0.01).",Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
| Household Income and Childhood Asthma Page 5 of 7  EHThttp://e-eht.org/search.,Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
Page 6 of 7Environmental Health and Toxicology    2012;27:e2012020 EHT http://e-eht.org/disparity is dependent on household income.,Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
Available  from: http://isaac.auckland.ac.nz/phases/phasethree/results/re - sults.php.,OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
| Household Income and Childhood Asthma Page 7 of 7  EHThttp://e-eht.org/30.,Non-OADS,/arxiv_data1/oa_pdf/c7/6c/eht-27-e2012020.PMC3524452.pdf
"Copyright © 2012 The Korean Society of Environmental Health and T oxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7 EHThttp://e-eht.org/Background The Korean Research Project on Integrated Exposure Assess - ment to Hazardous Materials for Food Safety (KRIEFS) was as - sembled by the Institute of Food and Drug Safety Evaluation, a  subsidiary of the Korea Food and Drug Administration, on  March 2010, to conduct a nationwide survey of infants, chil - dren, teenagers, and adults in order to observe and assess their  dietary intake and exposure to hazardous materials.",Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
"Keywords  Hazardous materials, Exposure, Assessment, Cohort studiesCorrespondence:  Ji-Ae Lim 119 Dandae-ro, Dongnam-gu,  Cheonan 330-714, Korea T el: +82-41-550-3868 Fax: +82-41-550-6461  E-mail: limjiae@gmail.com Received:  April 24, 2012 Accepted:  August 24, 2012 Published online:  November 30, 2012 This article is available from: http:// e-eht.org/Volume: 27, Article ID: e2012019, 7 pages   http://dx.doi.org/10.5620/eht.2012.27.e2012019  EHTEnvironmental Health and Toxicology eISSN: 2233-6567 •  Meeting  Report  Open Access",Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
Page 2 of 7Environmental Health and Toxicology    2012;27:e2012019 EHT http://e-eht.org/able to receive feedback and advice from experts in their field.,Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
"| Hazardous Materials Integrated Exposure Assessment  Page 3 of 7  EHThttp://e-eht.org/20 years and older in 2009 to persons 10 years and older after  2010, but did not include minors under 10 or infants in the study.",Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
"Page 4 of 7Environmental Health and Toxicology    2012;27:e2012019 EHT http://e-eht.org/the KNHANES, is also a cross-sectional study and cannot es - tablish a causal relationship between environmental exposure  and the concentration of hazardous material in the human body.",Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
"| Hazardous Materials Integrated Exposure Assessment  Page 5 of 7  EHThttp://e-eht.org/Through blood and urine samples collected from survey sub - jects, NHEXAS measures about 120 toxic materials, including  heavy metals and agricultural chemicals.",OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
Page 6 of 7Environmental Health and Toxicology    2012;27:e2012019 EHT http://e-eht.org/veloping methods in endocrine disruptors’ survey.,Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
"| Hazardous Materials Integrated Exposure Assessment  Page 7 of 7  EHThttp://e-eht.org/Specifically, three studies have analysed children’s growth, devel - opment, allergies, exposure to heavy metals and endocrine disrup - tors using human specimen collected from birth to a specific age.",Non-OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
Available from:  http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/nhanes07  _08.htm.,OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
Available from: http://www.cdc.gov/exposurereport/index.html.,OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
Available from:  http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/chms-ec - ms/index-eng.php.,OADS,/arxiv_data1/oa_pdf/70/c4/eht-27-e2012019.PMC3524453.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ba/8a/srep00994.PMC3524519.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Bu¨cker, R. et al.Helicobacter pylori colonization critically depends on postprandial gastric conditions.",Non-OADS,/arxiv_data1/oa_pdf/ba/8a/srep00994.PMC3524519.pdf
"Spheroid radius was then measured from digital photomicrographs using the image analysis softwareImageJ64-1.45i (http://imagej.nih.gov), calculating the spheroid projected areas and assuming a spherical shape.",OADS,/arxiv_data1/oa_pdf/cc/85/srep00990.PMC3524520.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/cc/85/srep00990.PMC3524520.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Milotti, E., Vyshemirsky, V., Sega, M. & Chignola, R. Interplay between distribution of live cells and growth dynamics of solid tumours.",Non-OADS,/arxiv_data1/oa_pdf/cc/85/srep00990.PMC3524520.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/89/74/srep00991.PMC3524521.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Badugu, A., Kraemer, C., Germann, P., Menshykau, D. & Iber, D. Digit patterning during limb development as a result of the BMP-receptor interaction.",Non-OADS,/arxiv_data1/oa_pdf/89/74/srep00991.PMC3524521.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreportsCompeting financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/dc/bc/srep00995.PMC3524523.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Wang, H.T.",Non-OADS,/arxiv_data1/oa_pdf/dc/bc/srep00995.PMC3524523.pdf
http://www.condmatjournalclub.org/ ?p51251 (2011).,Non-OADS,/arxiv_data1/oa_pdf/d1/46/srep00992.PMC3524549.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/d1/46/srep00992.PMC3524549.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Sorella, S., Otsuka, Y.",Non-OADS,/arxiv_data1/oa_pdf/d1/46/srep00992.PMC3524549.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b7/ac/srep00989.PMC3524551.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Baac, H.W.",Non-OADS,/arxiv_data1/oa_pdf/b7/ac/srep00989.PMC3524551.pdf
Journal of Histochemistry & Cytochemistry 60(10) 749 –760 © The Author(s) 2012 Reprints and permission:   sagepub.com/journalsPermissions.nav DOI: 10.1369/0022155412457048 http://jhc.sagepub.com The pancreatic islet is a complex mini-organ comprising  numerous cell types.,Non-OADS,/arxiv_data1/oa_pdf/24/13/10.1369_0022155412457048.PMC3524560.pdf
"Journal of Histochemistry & Cytochemistry 60(10) 734 –748 © The Author(s) 2012 Reprints and permission:   sagepub.com/journalsPermissions.nav DOI: 10.1369/0022155412458436 http://jhc.sagepub.com Long bones are formed by the process of endochondral  ossification (Karsenty 2003; Kronenberg 2003; Provot and Schipani 2005, 2007; Mackie et al.",Non-OADS,/arxiv_data1/oa_pdf/88/cb/10.1369_0022155412458436.PMC3524565.pdf
Measurements were analyzed by one-way ANOV A using online software (http://faculty.vassar.edu/lowry/anova1u.html) for statisti-cal significance.,OADS,/arxiv_data1/oa_pdf/88/cb/10.1369_0022155412458436.PMC3524565.pdf
Measurements were analyzed by one-way ANOV A using online software (http://faculty.vassar.edu/lowry/anova1u.html) for statisti-cal significance.,OADS,/arxiv_data1/oa_pdf/88/cb/10.1369_0022155412458436.PMC3524565.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society Biochemical Journal    www.biochemj.org © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
The generation scheme of the pAA V-based targeting vector isshown in Supplementary Figure S1 (at http://www.biochemj.org/bj/449/bj4490459add.htm).,Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
The primer sequences used for the PCRsare shown in Supplementary Table S1 (at http://www.biochemj.,Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"Cells c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
Statistical analysis for microarray data was performed using R and BioConductor software (http://www.bioconductor.org/).,OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"This different expression pattern of c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"These results indicated that the loss of LSD1 did not affect the function of p53 induced by the DNA damage response with respect to p21 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
The results conﬁrmed that LSD1 is present at the proximal promoter of p21 in wild-type HCT116 cells (Supplementary Figure S2 at http://www.biochemj.org/bj/449/bj4490459add.htm).,Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"However, there was no indication that the decrease in the growth rate wasaccompanied by an increase in apoptosis, as there was no change c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"Ananalysis of the functionally related gene groups among our up- or c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"The results of the present study are surprising in that the loss of LSD1 did not alter the global levels of H3K4 methylation or c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"13, 626–632 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"Cancer 131, 1423–1434 Received 28 August 2012/15 October 2012; accepted 17 October 2012 Published as BJ Immediate Publication 17 October 2012, doi:10.1042/BJ20121360 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"The underlined sequence represents XhoI and NotI sites PA GTGGAAACCATGTTGTCTTTG Forward primer for screening for the ﬁrst allele recombinationPB AAGTCATGCCCGCTTTTG Reverse primer for screening for the ﬁrst allele recombinationPC GGAAACCATGTTGTCTTTGC Forward primer for screening for the second allele recombination PD CATATGCACAGTGGTACCTT Reverse primer for screening for the second allele recombination AIM1-F TGGAGCTTGAAGTCCGATG Forward primer for qPCRAIM1-R CCCACACTTGTGTAAACTTCTC Reverse primer for qPCRVIM-F GCGTGACGTACGTCAGCAATA Forward primer for qPCR VIM-R GCGGCCAATAGTGTCTTGGTA Reverse primer for qPCR SKAP1-F GGGTGACCTCATCCGTATTC Forward primer for qPCRSKAP1-R CCTCATAAAGGCAGGAGAGAG Reverse primer for qPCRDNER-F ACAGCGAGTTCAGCAATG Forward primer for qPCR DNER-R TTTTAATCAGTGTGACCAAGGG Reverse primer for qPCR VAT1L-F ATCAAGCCTGTGGTGGACTC Forward primer for qPCRVAT1L-R TGCTTCACTGGTCTCTGTGC Reverse primer for qPCRIL8-F TGAGAGTGATTGAGAGTGGAC Forward primer for qPCR IL8-R CACTGATTCTTGGATACCACAG Reverse primer for qPCR IFI6-F TGGTCTGCGATCCTGAATG Forward primer for qPCRIFI6-R CTCATCCTCCTCACTATCGAG Reverse primer for qPCR SLC2A3-F GCGGGTGTGGTTAATACTATC Forward primer for qPCR SLC2A3-R GCCCCAATACAGACAAAGC Reverse primer for qPCRARHGAP24-F TGCACAGTTTAGTTTCCAGC Forward primer for qPCRARHGAP24-R GAACTTTTTCCTCTCCTGATCC Reverse primer for qPCR HIST1H4K-F AAGTACTGCGCGACAATATC Forward primer for qPCR HIST1H4K-R TCTCCAGGAACACCTTCAG Reverse primer for qPCRCDH1-F ATGAGTGTCCCCCGGTATCTTC Forward primer for qPCRCDH1-R CGGAACCGCTTCCTTCATAGTC Reverse primer for qPCR ZNF165-F AGCAGTACTCCAGGTTCAAG Forward primer for qPCR ZNF165-R TCACTCTCATTATCACAGTCCC Reverse primer for qPCRLSD1-F GCTCGGGGCTCTTATTCCTA Forward primer for qPCRLSD1-R CCCAAAAACTGGTCTGCAAT Reverse primer for qPCR TNFSF18-F GTTGCTATTTCTTTGCTCCTTC Forward primer for qPCR TNFSF18-R CCAGTCAGACACCTTATTCAC Reverse primer for qPCRRAB25-F CGTGGGTAACAAAAGTGACC Forward primer for qPCRRAB25-R CTAGCTCAACATTGGTAGAGTC Reverse primer for qPCR GAPDH-F GAAGGTGAAGGTCGGAGTC Forward primer for qPCR GAPDH-R GAAGATGGTGATGGGATT Reverse primer for qPCRVAT1L-ChIP-F7 ACATTCAACAGGAGGAACCC Forward primer for qPCR for ChIP VAT1L-ChIP-R7 TTTGACGCGGATCTTGAGC Reverse primer for qPCR for ChIP VIM-ChIP-F8 GCTGTAAGTTGGTAGCACTGA Forward primer for qPCR for ChIPVIM-ChIP-R8 TTCTGTCGAGGGACCTAACG Reverse primer for qPCR for ChIPIFI6-ChIP-F3 TGGTGATCAGGCTTCACTAAG Forward primer for qPCR for ChIP IFI6-ChIP-R3 CTGCAGTTTCATTTTCCCCTC Reverse primer for qPCR for ChIP IL8-ChIP-F3 GATCTTGTTCTAACACCTGCC Forward primer for qPCR for ChIPIL8-ChIP-R3 GCAAACCTGAGTCATCACAC Reverse primer for qPCR for ChIPp21-ChIP-F1 GGGGCGGTTGTATATCAGG Forward primer for qPCR for ChIP p21-ChIP-R1 GGCTCCACAAGGAACTGACT Reverse primer for qPCR for ChIP p21-ChIP-F2 CTCTCCAATTCCCTCCTTCC Forward primer for qPCR for ChIPp21-ChIP-R2 AGAAGCACCTGGAGCACCTA Reverse primer for qPCR for ChIP Received 28 August 2012/15 October 2012; accepted 17 October 2012 Published as BJ Immediate Publication 17 October 2012, doi:10.1042/BJ20121360 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2013 Biochemical Society © 2013 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/9a/bj4490459.PMC3525012.pdf
"MATERIALS AND METHODS     In this retrospective study, required information about  journal IFs and total citation times of “Nutrition and  Dietetics” category of ISI journals were collected for the  last 10-year period (1999-2008) through JCR of Thomson  Reuter Web of Knowledge (http://apps.isiknowledge.com).",OADS,/arxiv_data1/oa_pdf/28/6e/JRMS-17-128.PMC3525028.pdf
Available from: http://www.thomsonreuters.com   products_services/science/academic/impact_factor/.,OADS,/arxiv_data1/oa_pdf/28/6e/JRMS-17-128.PMC3525028.pdf
Available   from: http://www.mathunion.org/fileadmin/IMU/Report/  CitationStatistics.pdf [Last  accessed on 2010.03.05 ]  16.,OADS,/arxiv_data1/oa_pdf/28/6e/JRMS-17-128.PMC3525028.pdf
Available from : http://www.hivinsite.,Non-OADS,/arxiv_data1/oa_pdf/b1/9c/JRMS-17-138.PMC3525030.pdf
Available from: URL:  http://www.dhed.net/ASA%20Physical%20Status%20Classificati on%20SYSTEM.htm.,Non-OADS,/arxiv_data1/oa_pdf/44/91/JRMS-17-143.PMC3525031.pdf
Available from: http://www.consensus.nih.gov/2004/2   004CeliacDisease118html.htm.,OADS,/arxiv_data1/oa_pdf/e3/6e/JRMS-17-154.PMC3525033.pdf
Available from: http://www.wo kinfo.com/   products_tools/multidisciplinary/webofscience [Last  cited on   2011 Oct 26].,OADS,/arxiv_data1/oa_pdf/ee/0a/JRMS-17-171.PMC3525037.pdf
Available from: http://www.nlm.nih.g ov/pubs/   factsheets/medline.html [Last cited on 2011 Oct 26].,Non-OADS,/arxiv_data1/oa_pdf/ee/0a/JRMS-17-171.PMC3525037.pdf
Available from: http://www.commis sion.hbi.ir   [Last cited on 2011 Oct 26].,Non-OADS,/arxiv_data1/oa_pdf/ee/0a/JRMS-17-171.PMC3525037.pdf
Available from:   http://www.thomsonreuters.com/products_services/sci ence/free/   essays/journal_selection_process [Last cited on 2011 Oct 26].,Non-OADS,/arxiv_data1/oa_pdf/ee/0a/JRMS-17-171.PMC3525037.pdf
CDC: The CAUSE (careful antibiotic use to prevent resistance);   Available from: http://www.cdc.gov/ncidod/dbmd/cause/oct97.,Non-OADS,/arxiv_data1/oa_pdf/1c/0b/JRMS-17-182.PMC3525039.pdf
[cited 2008 Dec 10]; Av ailable from:  URL: http://www.who.int/tb/publications/  global report/  2008/en/index.html.,OADS,/arxiv_data1/oa_pdf/50/20/JRMS-17-199.PMC3525043.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/2.0/ uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cc/4e/aws273.PMC3525052.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by- nc/3.0/), which permits non- commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2a/8f/aws275.PMC3525053.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/01/71/aws277.PMC3525054.pdf
"Volumes of each tissue type were extracted (get_totals65.m; http://www.cs.ucl.ac.uk/staff/G.Ridgway/vbm/), and each grey matter volume was divided by the corresponding total intracranial volume (i.e.",OADS,/arxiv_data1/oa_pdf/01/71/aws277.PMC3525054.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e0/d0/aws292.PMC3525057.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c8/52/aws296.PMC3525058.pdf
"Image processing and statistical testing Analyses reported here were conducted using a combination of toolsfrom the FMRIB software library (FSL) (Smith et al., 2004a, http:// www.fmrib.ox.ac.uk/fsl), SPM8 (Wellcome Trust Centre forNeuroimaging, London, England, http://www.ﬁl.ion.ucl.ac.uk/spm)and nipy (Millman and Brett, 2007, http://nipy.sourceforge.net) soft-ware toolkits.3636 |Brain 2012: 135; 3635–3644 J. O’Muircheartaigh et al.",OADS,/arxiv_data1/oa_pdf/c8/52/aws296.PMC3525058.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0e/32/aws298.PMC3525059.pdf
"The predicted promoter region of POLG was determined from the Transcriptional Regulatory Element Database (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process =home), and direct Sanger sequencing of this entire promoter was performed (Supplementary material).",Non-OADS,/arxiv_data1/oa_pdf/0e/32/aws298.PMC3525059.pdf
"Many single nucleotide polymorphisms have been reported in POLG , some of them with high frequency in Caucasian popula- tions (http://tools.niehs.nih.gov/polg/, Supplementary material).In one of the diagnostic laboratories involved in this study Medical Genetics Center, diagnostic sequencing of the entire coding region of POLG with ﬂanking intronic sequences showed that 620 out of 897 ( /C2470%) patients from independent families carried different single nucleotide polymorphisms in POLG , indi- cating that the wild-type sequence is much less frequent than the presence of single nucleotide polymorphisms (data not shown).",Non-OADS,/arxiv_data1/oa_pdf/0e/32/aws298.PMC3525059.pdf
NHS Specialist Commissioners which funds the ‘Rare Mitochondrial Disorders of Adults and Children’ DiagnosticService in Newcastle upon Tyne (http://www.mitochondrialncg.nhs.uk) for R.W.T.,Non-OADS,/arxiv_data1/oa_pdf/0e/32/aws298.PMC3525059.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/fe/aws311.PMC3525062.pdf
"Groups of si milar sequences were aligned using a global alignment algorithm, and the NCBI OrfFinder(http://www.ncbi.nlm.nih.gov/projects/gorf/ ) was used to detect ORFs in autonomous transposon sequences.",OADS,/arxiv_data1/oa_pdf/b6/15/mss206.PMC3525145.pdf
Codon optimization of the sequences was performed usingPrimo Optimum 3.4 ( http://www.chang bioscience.com/ primo/primoo.html ).,OADS,/arxiv_data1/oa_pdf/f9/d5/mss202.PMC3525338.pdf
"To identify genomic copies of L1PA8, we used the pub- lished L1PA8 consensus as a BLAT query (UCSC GenomeBrowser, hg19 Assembly: http://genome.ucsc.edu/cgi-bin/ hgBlat ) and identiﬁed 23 genomic copies that were full-length or near-full-length elements annotated as L1PA8.",OADS,/arxiv_data1/oa_pdf/f9/d5/mss202.PMC3525338.pdf
"To validate these L1 copies as belonging to the L1PA8subfamily, we queried these 23 copies to Repeat Masker(http://www.repeatmasker.org/ ).",OADS,/arxiv_data1/oa_pdf/f9/d5/mss202.PMC3525338.pdf
Supplementary Material Supplementary ﬁgures S1–S4 a r ea v a i l a b l ea t Molecular Biology and Evolution online ( http://www.mbe.oxfordjour- nals.org/).,Non-OADS,/arxiv_data1/oa_pdf/f9/d5/mss202.PMC3525338.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Non-Commercial Attribution License (http://creativecommons.org/licenses/by-nc/3.0), which perm its non-commercial use, distrib ution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/99/f3/mss212.PMC3525417.pdf
"2009 )h o s t e db y the Institut Pasteur ( http://mobyle.pasteur.fr , last accessed September 2012).",Non-OADS,/arxiv_data1/oa_pdf/99/f3/mss212.PMC3525417.pdf
http://dx.doi.org/ 10.1016/j.ympev.2012.07.,OADS,/arxiv_data1/oa_pdf/99/f3/mss212.PMC3525417.pdf
"The first that comes to mind is the effort of harmoniz - ing the use of immune monitoring assays in multi-center clinical trials through a data-driven, SOP-based process that enables individual centers to use their own Advancing the field of cancer immunotherapy MIATA consensus guidelines become available to improve  data reporting and interpretation for T-cell immune  monitoring axel Hoos,1,3,* Sylvia Janetzki2,3 and Cedrik M. Britten4,5 1Glaxo Smith Kline; Collegeville, P a US a; 2Zellnet Consulting; Fort Lee, NJ US a; 3Cancer Immunotherapy Consortium; Cancer r esearch Institute; New York, NY US a;  4translational Oncology; University Medical Center of the Johannes Gutenberg-University Mainz GmbH; Mainz, Germany; 5association for Cancer Immunotherapy (CIM t);  Mainz, Germany *Correspondence to: Axel Hoos; Email: axel.x.hoos@gsk.com Submitted: 09/05/12; Accepted: 09/06/12http://dx.doi.org/10.4161/onci.22308assay protocols and still achieve a low level  of data variability across centers.5 This  program has been running since 2005 and has delivered practical recommen - dations for the community based on the recognition of critical experimental vari - ables that impact assay performance and should be reported to assess the results.",Non-OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
N Engl J Med 2010; 363:411-22;  PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992;  http://dx.doi.org/10.1056/NEJMoa1003466.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
J Natl Cancer Inst  2010; 102:1388-97; PMID:20826737; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Nat Biotechnol 2011; 29:867-70; PMID:21997622; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Sci T ransl  Med 2011; 3:08ps44; PMID:22072636; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Cancer Immunol Immunother 2008; 57:285-8;  PMID:17721782; http://dx.doi.org/10.1007/s00262- 007-0379-z.7.,Non-OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Immunity 2009; 31:527-8; PMID:19833080; http://dx.doi.org/10.1016/j.immu- ni.2009.09.007.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Immunity 2012; 37:1-2; PMID:22840835;  http://dx.doi.org/10.1016/j.immuni.2012.07.010.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Nat Genet 2001; 29:365-71;  PMID:11726920; http://dx.doi.org/10.1038/ng1201- 365.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Oncoimmunology 2012; 1:334-9; PMID:22737609;  http://dx.doi.org/10.4161/onci.19268.11.,Non-OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
Nat Biotechnol  2008; 26:889-96; PMID:18688244; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/bf/onci-1-1457.PMC3525600.pdf
"OncoImmunology 1:9, 1460–1468; December 2012; © 2012 Landes Bioscience ReseaR ch papeR 1460 OncoImmunology Volume 1 Issue 9*Correspondence to: George C. Prendergast; Email: prendergast@limr.org Submitted: 07/29/12; Accepted: 08/03/12http://dx.doi.org/10.4161/onci.21716Introduction Indoleamine 2,3-dioxygenase (IDO) catalyzes the first rate-lim - iting step in the breakdown of the essential amino acid trypto - phan (Trp).",Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Am J Pathol 2010; 176:2082- 7; PMID:20228228; http://dx.doi.org/10.2353/ ajpath.2010.091173.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Oncogene 2008; 27:3889- 900; PMID:18317452; http://dx.doi.org/10.1038/ onc.2008.35.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Cancer Discov 2012; 2:722-35; PMID:22822050; http://dx.doi.org/10.1158/2159-8290.CD-12-0014.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
J Immunol  2011; 186:4535-40; PMID:21464094; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Proc Natl Acad Sci U S A  2008; 105:17073-8; PMID:18952840; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Cancer Res 2007; 67:792-801;  PMID:17234791; http://dx.doi.org/10.1158/0008- 5472.CAN-06-2925.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Immunity 2005; 22:633-42; PMID:15894280; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Science 2009; 324:1334- 8; PMID:19498172; http://dx.doi.org/10.1126/sci- ence.1172638.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Annu Rev Pharmacol Toxicol 2012; 52:381-400;  PMID:22017684; http://dx.doi.org/10.1146/annurev- pharmtox-010611-134537.10.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Nat Immunol 2011; 12:1113-8;  PMID:21983831; http://dx.doi.org/10.1038/ni.2121.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Cancer Immunol Immunother  2010; 59:1655-63; PMID:20640572; http://dx.doi.org/10.1007/s00262-010-0891-4.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
"J Am Coll Surg 2009; 208:781- 7, discussion 787-9; PMID:19476837; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Nature  2011; 478:197-203; PMID:21976023; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Nat Med 2005; 11:312-9; PMID:15711557; http://dx.doi.org/10.1038/nm1196.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Cancer Res 2007; 67:7082-7; PMID:17671174; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
J Biol Chem 2010; 285:16893-911; PMID:20233714;  http://dx.doi.org/10.1074/jbc.M110.121947.19.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Mol Cell Biol  2010; 30:2862-73; PMID:20404097; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Biochem Soc T rans 2011; 39:443-5; PMID:21428916;  http://dx.doi.org/10.1042/BST0390443.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Biochem J  2007; 403:13-20; PMID:17253963; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Heart Vessels 2011; 26:69-80; PMID:20963594;  http://dx.doi.org/10.1007/s00380-010-0032-1.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Curr Opin Immunol 2010; 22:655-61; PMID:20833524;  http://dx.doi.org/10.1016/j.coi.2010.08.010.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Nat  Med 2007; 13:54-61; PMID:17187072; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Cancer Immunol  Immunother 2012; PMID:22527253; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
PLoS One  2011; 6:e19823; PMID:21625531; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Nat Rev Cancer 2009; 9:445-52; PMID:19461669; http://dx.doi.org/10.1038/nrc2639.28.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Mol Immunol  2009; 46:2071-9; PMID:19356803; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
Mol Immunol 2008; 46:213-24; PMID:18842300;  http://dx.doi.org/10.1016/j.molimm.2008.08.275.,Non-OADS,/arxiv_data1/oa_pdf/db/4b/onci-1-1460.PMC3525601.pdf
"www.landesbioscience.com OncoImmunology 1469OncoImmunology 1:9, 1469–1475; December 2012; © 2012 Landes Bioscience ReseaR ch papeR ReseaR ch papeR *Correspondence to: Joseph Tuscano; Email: joseph.tuscano@ucdmc.ucdavis.edu Submitted: 07/10/12; Revised: 08/08/12; Accepted: 08/11/12http://dx.doi.org/10.4161/onci.21815Introduction Monoclonal antibodies (mAbs) have demonstrated utility in can - cer research and treatment because of their exquisite specificity  and relatively manageable side effects.",Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
J Clin Oncol 2012; 30:1822- 8; PMID:22355053; http://dx.doi.org/10.1200/ JCO.2011.38.1756.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Cancer Sci 2012; 103:933-8; PMID:22335424; http://dx.doi.org/10.1111/j.1349-7006.2012.02241.x.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Clin Cancer Res  2010; 16:1894-903; PMID:20215554; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Adv Immunol 2005; 88:1-50;  PMID:16227086; http://dx.doi.org/10.1016/S0065- 2776(05)88001-0.,OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Cancer Immunol Immunother 2009; 58:1715-22;  PMID:19294384; http://dx.doi.org/10.1007/s00262- 009-0688-5.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Cancer Immunol Immunother 2009; 58:2051- 8; PMID:19437017; http://dx.doi.org/10.1007/s00262-009-0713-8.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Leuk Res 2009; 33:964-9;  PMID:19237192; http://dx.doi.org/10.1016/j.leu- kres.2009.01.026.,OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
J Hematol Oncol 2011; 4:49; PMID:22128838;  http://dx.doi.org/10.1186/1756-8722-4-49.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Leukemia 2010;  24:1566-73. http://dx.doi.org/10.1038/leu.2010.141;  PMID:20596033 15.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Blood 2004; 103:1807-14;  PMID:14615373; http://dx.doi.org/10.1182/blood- 2003-07-2466.18.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Br J Haematol 1998; 101:179-88;  PMID:9576199; http://dx.doi.org/10.1046/j.1365- 2141.1998.00665.x.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Br  J Cancer 2001; 84:571-8; PMID:11207056; http://dx.doi.org/10.1054/bjoc.2000.1633.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Cancer Res  2006; 66:2271-8; PMID:16489031; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Toxins (Basel) 2011; 3:697-720; PMID:22069735; http://dx.doi.org/10.3390/ toxins3060697.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Leuk Res  1996; 20:607-17; PMID:8795695; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
Virchows Arch B Cell Pathol  Incl Mol Pathol 1987; 53:259-71; PMID:2889289;  http://dx.doi.org/10.1007/BF02890252.,Non-OADS,/arxiv_data1/oa_pdf/92/d8/onci-1-1469.PMC3525602.pdf
"OncoImmunology 1:9, 1476–1483; December 2012; © 2012 Landes Bioscience ReseaR ch papeR 1476 OncoImmunology Volume 1 Issue 9*Correspondence to: Inge Marie Svane; Email: inge.marie.svane@regionh.dk Submitted: 08/17/12; Accepted: 08/23/12http://dx.doi.org/10.4161/onci.21940Introduction Treatment of BRAFV600E mutant melanoma with vemurafenib  (Vem), a selective BRAF inhibitor, has been shown to result in  impressive rates (up to 50%) of objective responses and improved progression-free and overall survival, as compared with standard chemotherapy.",Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
"Cell lines FM57 ( BRAFV600K), FM88 ( BRAFV600K) and FM92  (BRAFV600E) (from the ESTDAB, see http://www.ebi.ac.uk/ipd/ estdab/ for further information) were a gift of Straten PT.",Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
N Engl J Med 2011;  364:2507-16; PMID:21639808; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Clin Cancer Res 2011; 17:4550-7; PMID:21498393;  http://dx.doi.org/10.1158/1078-0432.CCR-11-0116.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Clin Cancer Res 2011; 17:1664-73; PMID:21325070; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Clin Cancer Res 2012; 18:2326-35;  PMID:22355009; http://dx.doi.org/10.1158/1078- 0432.CCR-11-2515.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Clin Cancer Res  2010; 16:6040-8; PMID:21169256; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Cancer Res  2010; 70:5213-9; PMID:20551059; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Cancer Res  2012; 72:1642-50; PMID:22311675; http://dx.doi.org/10.1158/0008-5472.CAN-11-2614.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Oncoimmunology 2012; 1:409- 18; PMID:22754759; http://dx.doi.org/10.4161/onci.18851.11.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Cancer Res 2012; 72:1642-50;  PMID:22693252; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2837.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Cell Immunol 2012; 273:1- 9; PMID:22230732; http://dx.doi.org/10.1016/j.cel- limm.2011.12.004.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Cancer Immunol  Immunother 2009; 58:665-75; PMID:18828018;  http://dx.doi.org/10.1007/s00262-008-0588-0.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J Immunother  2001; 24:323-33; PMID:11565834; http://dx.doi.org/10.1097/00002371-200107000-00008.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Nat Protoc 2012; 7:891- 902; PMID:22498709; http://dx.doi.org/10.1038/ nprot.2012.037.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Nat Protoc 2006; 1:1120-32;  PMID:17406393; http://dx.doi.org/10.1038/ nprot.2006.121.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J Immunol Methods 2009; 340:90- 4; PMID:18957296; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Proc Natl Acad Sci U S A 2008; 105:1662- 7; PMID:18216248; http://dx.doi.org/10.1073/ pnas.0711365105.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Curr Opin Immunol 2002; 14:45-51;  PMID:11790532; http://dx.doi.org/10.1016/S0952- 7915(01)00297-7.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Scand J Immunol 2011; In press;  PMID:21955245; http://dx.doi.org/10.1111/j.1365-3083.2011.02640.x.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J Clin Oncol 2009; 27:5931-7; PMID:19884549;  http://dx.doi.org/10.1200/JCO.2009.22.4295.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Oncogene  2007; 26:4738-48; PMID:17260012; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Cancer Res 2004; 64:1157-63;  PMID:14871852; http://dx.doi.org/10.1158/0008- 5472.CAN-03-2209.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J Exp Med  2006; 203:1651-6; PMID:16801397; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/10.1158/1078- 0432.CCR-11-2479.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J T ransl Med 2010; 8:39;  PMID:20406486; http://dx.doi.org/10.1186/1479- 5876-8-39.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J T ransl Med 2010; 8:67;  PMID:20630094; http://dx.doi.org/10.1186/1479- 5876-8-67.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
J Immunother  2011; 34:556-67; PMID:21760528; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/af/25/onci-1-1476.PMC3525603.pdf
"Sterling; Email: julie.sterling@vanderbilt.edu Submitted: 06/01/12; Revised: 08/21/12; Accepted: 08/27/12http://dx.doi.org/10.4161/onci.21990Introduction Breast cancer, which is the second leading cause of death among  women, represents 30% of all malignancies affecting women.1  While much progress has been made in diagnosis and therapeutic options, resulting in improved survival rates, a substantial num - ber of breast cancer patients are still diagnosed with advanced disease, and up to 80% of them develop bone metastases.",Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Supplemental Material Supplemental materials may be found here: http://www.landesbioscience.com/journals/oncoimmunology/article/21990/and phloxine for Tumor burden analysis.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Res 2006; 66:7548-53;  PMID:16885353; http://dx.doi.org/10.1158/0008- 5472.CAN-06-0452.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
J Exp Med  1982; 156:1604-14; PMID:7175438; http://dx.doi.org/10.1084/jem.156.6.1604.,OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
J Exp Med 2010; 207:2439- 53; PMID:20876310; http://dx.doi.org/10.1084/ jem.20100587.,OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Nat Rev Cancer  2002; 2:584-93; PMID:12154351; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Endocr Relat Cancer  2009; 16:703-13; PMID:19443538; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Immunol Immunother  2004; 53:422-30; PMID:14648070; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Immunol Immunother 2006; 55:237-45;  PMID:16047143; http://dx.doi.org/10.1007/s00262-005-0048-z.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
J Clin Invest  1996; 98:1544-9; PMID:8833902; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Res 2004; 64:5839-49;  PMID:15313928; http://dx.doi.org/10.1158/0008- 5472.CAN-04-0465.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Immunol Rev  2008; 222:162-79; PMID:18364001; http://dx.doi.org/10.1111/j.1600-065X.2008.00602.x.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Cell 2008; 13:23- 35; PMID:18167337; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
J Bone Miner Res 2010; 25:1701- 6; PMID:20572008; http://dx.doi.org/10.1002/ jbmr.154.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Cell  2004; 6:409-21; PMID:15488763; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Res 2011; 71:822-31;  PMID:21189326; http://dx.doi.org/10.1158/0008- 5472.CAN-10-2993.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Res 2007; 67:11438-46; PMID:18056472;  http://dx.doi.org/10.1158/0008-5472.CAN-07-1882.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Int Immunopharmacol 2007; 7:140- 51; PMID:17178380; http://dx.doi.org/10.1016/j.intimp.2006.09.021.,OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Metastasis Rev 2006; 25:323-31;  PMID:16983515; http://dx.doi.org/10.1007/s10555- 006-9002-6.References 1.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
CA Cancer J Clin 2012; 62:10-29;  PMID:22237781; http://dx.doi.org/10.3322/ caac.20138.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Eur J Cancer 2012; 48:187-95; PMID:22100904;  http://dx.doi.org/10.1016/j.ejca.2011.10.021.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer T reat  Rev 2001; 27:165-76; PMID:11417967; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Breast Cancer Res T reat  1994; 32:73-84; PMID:7819589; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Bone 2011; 48:6- 15; PMID:20643235; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Adv Exp Med Biol 2007; 601:213-23;  PMID:17713008; http://dx.doi.org/10.1007/978-0- 387-72005-0_22.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer J 2010; 16:348- 53; PMID:20693846; http://dx.doi.org/10.1097/ PPO.0b013e3181eb3358.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Curr Opin  Immunol 2010; 22:238-44; PMID:20171075; http://dx.doi.org/10.1016/j.coi.2010.01.021.,OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Nat Rev  Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Cancer Res 2007; 67:4507-13; PMID:17483367; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
Semin Cancer  Biol 2006; 16:53-65; PMID:16168663; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/19/onci-1-1484.PMC3525604.pdf
"www.landesbioscience.com OncoImmunology 1495 ReseaR ch papeR ReseaR ch papeR OncoImmunology 1:9, 1495–1506; December 2012; © 2012 Landes Bioscience *Correspondence to: Awashti Shanjana; Email: Shanjana-Awasthi@ouhsc.edu Submitted: 07/01/12; Revised: 08/29/12; Accepted: 09/05/12http://dx.doi.org/10.4161/onci.22089Introduction Colorectal cancer is the third most common cancer and leading  cause of cancer-related mortality in the United States.",Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Pharm Sci  2012; 101:2668-74; PMID:22573521; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Inflamm Bowel Dis 2011; 17:1464- 73; PMID:21674704; http://dx.doi.org/10.1002/ibd.21527.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
PLoS One  2010; 5:e9891; PMID:20360984; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Clin Immunol 2004; 112:85-91;  PMID:15207785; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Mol Immunol 2007; 44:2850- 9; PMID:17328955; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Oncogene 2009; 28:4353-63; PMID:19826413;  http://dx.doi.org/10.1038/onc.2009.289.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Br J Cancer 2009; 100:1589-602;  PMID:19436306; http://dx.doi.org/10.1038/ sj.bjc.6604942.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Cancer Res 2011; 71:1989-98; PMID:21363926; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Pharmacol  Exp Ther 2011; 336:672-81; PMID:21159752; http://dx.doi.org/10.1124/jpet.110.173765.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Biol Chem 1995; 270:12162- 9; PMID:7744866; http://dx.doi.org/10.1074/jbc.270.20.12162.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Coccidioides posadasii infection alters the expression of pulmo- nary surfactant proteins (SP)-A and SP-D. Respir  Res 2004; 5:28; PMID:15588319; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Cell Immunol 2011; 268:87-96;  PMID:21439559; http://dx.doi.org/10.1016/j.cel - limm.2011.02.009.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Biol Chem 2006; 281:21771- 80; PMID:16754682; http://dx.doi.org/10.1074/jbc.M513041200.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Nature  2009; 458:1191-5; PMID:19252480; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Cancer Res 2009; 69:3105-13;  PMID:19318560; http://dx.doi.org/10.1158/0008- 5472.CAN-08-3838.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Prostate 2009; 69:1387-97; PMID:19496069; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Leukoc Biol  2009; 86:557-66; PMID:19451397; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Comput  Chem 1986; 7:565-77; http://dx.doi.org/10.1002/ jcc.540070419.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Am J Respir Crit Care Med 2004; 169:187-94; PMID:14563656; http://dx.doi.org/10.1164/ rccm.200307-971OC.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Exp Med  1998; 188:2163-73; PMID:9841929; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Cancer Res 2004; 64:4569-76;  PMID:15231668; http://dx.doi.org/10.1158/0008- 5472.CAN-04-0202.34.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Exp Clin Cancer Res 2010; 29:92; PMID:20618976; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Mol Pain 2010; 6:2;  PMID:20089147; http://dx.doi.org/10.1186/1744- 8069-6-2.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Ann Surg Oncol  2009; 16:1043-50; PMID:19165543; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Pediatr Pathol Mol Med 2001;  20:319-39; PMID:11486736; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Recent Pat Antiinfect Drug Discov  2010; 5:115-23; PMID:20230362; http://dx.doi.org/10.2174/157489110791233559.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Am J Respir Cell Mol Biol 2004; 31:587-94;  PMID:15308505; http://dx.doi.org/10.1165/ rcmb.2004-0003OC.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
J Immunother  2010; 33:73-82; PMID:19952954; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Nature  1992; 356:768-74; PMID:1574116; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Cytokine 1990; 2:190- 8; PMID:2151765; http://dx.doi.org/10.1016/1043- 4666(90)90015-L. 27.,OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Cancer Res 2006; 66:3859-68; PMID:16585214; http://dx.doi.org/10.1158/0008-5472.CAN-05-3948.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
Hum Immunol 2011; 72:1095-116; PMID:21872627; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/c5/onci-1-1495.PMC3525605.pdf
"www.landesbioscience.com OncoImmunology 1507 ReseaR ch papeR ReseaR ch papeR OncoImmunology 1:9, 1507–1516; December 2012; © 2012 Landes Bioscience *Correspondence to: Franca Ronchese; Email: fronchese@malaghan.org.nz Submitted: 07/30/12; Accepted: 09/08/12http://dx.doi.org/10.4161/onci.22128Introduction Dendritic cells (DCs) are powerful antigen-presenting cells  whose role in the initiation of primary CD4+ and CD8+ T-cell  immune responses, as well as in the reactivation of memory CD8 + T-cell responses, is well recognized.1 Because of their high  immunogenicity, DCs loaded with different types of antigenic tumor material, including peptides, tumor lysates or apoptotic tumor cells, have been used as vaccines in several studies of tumor immunotherapy (reviewed in ref.",Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Nature 1998; 392:245-52;  PMID:9521319; http://dx.doi.org/10.1038/32588.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/sci- ence.1203486.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Annu Rev Immunol 2006; 24:175-208;  PMID:16551247; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
J Exp Med 1998; 188:1641-50; PMID:9802976; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity 2008; 28:414-24; PMID:18342010; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Blood 2009; 114:1537-44; PMID:19423728;  http://dx.doi.org/10.1182/blood-2008-12-195792.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Clin Cancer Res 2007; 13:1757-61; PMID:17363529;  http://dx.doi.org/10.1158/1078-0432.CCR-06-2599.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
J  Immunother 1999; 22:71-9; PMID:9924702; http://dx.doi.org/10.1097/00002371-199901000-00010.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Cancer Res  2004; 64:2865-73; PMID:15087405; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Oncoimmunology 2012; 1:467- 530; PMID:22754765; http://dx.doi.org/10.4161/onci.19856.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Proc Natl Acad Sci U S A 2006; 103:147-52; PMID:16373503; http://dx.doi.org/10.1073/ pnas.0509054103.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity 1997; 6:715-26;  PMID:9208844; http://dx.doi.org/10.1016/S1074- 7613(00)80447-1.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
PLoS One  2012; 7:e37481; PMID:22649530; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Nat Immunol  2000; 1:47-53; PMID:10881174; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Nature 1994; 369:31-7; PMID:8164737;  http://dx.doi.org/10.1038/369031a0.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Cell 1994; 76:17- 27; PMID:8287475; http://dx.doi.org/10.1016/0092- 8674(94)90169-4.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunol Cell Biol 1998; 76:34-40; PMID:9553774;  http://dx.doi.org/10.1046/j.1440-1711.1998.00709.x.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Mol Cell Biol  2005; 25:2000-13; PMID:15713653; http://dx.doi.org/10.1128/MCB.25.5.2000-2013.2005.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Eur J Immunol 2008; 38:2886- 95; PMID:18825745; http://dx.doi.org/10.1002/ eji.200838483.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunol Cell  Biol 2010; 88:291-6; PMID:19997079; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Cancer Immunol Immunother 1997; 44:341- 7; PMID:9298937; http://dx.doi.org/10.1007/ s002620050392.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity 2003; 18:499-511;  PMID:12705853; http://dx.doi.org/10.1016/S1074- 7613(03)00081-5.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Blood 2012; 119:127-36;  PMID:22042696; http://dx.doi.org/10.1182/blood- 2011-06-363994.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity 2006; 24:451-61;  PMID:16618603; http://dx.doi.org/10.1016/j.immu-ni.2006.02.002.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/ nrc3239.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Cancer Res  2007; 67:7467-76; PMID:17671217; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
J Med Chem 2008; 51:7614- 24; PMID:19007200; http://dx.doi.org/10.1021/ jm801063n.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Science  1999; 286:1957-9; PMID:10583959; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Science 2000; 290:1354-8;  PMID:11082062; http://dx.doi.org/10.1126/sci- ence.290.5495.1354.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity  2003; 18:463-74; PMID:12705850; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Blood 2004; 104:735-43;  PMID:15069016; http://dx.doi.org/10.1182/blood-2003-10-3413.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Proc Natl Acad Sci U S A 2007; 104:6341- 6; PMID:17400753; http://dx.doi.org/10.1073/ pnas.0609990104.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Blood 2011; 118:618-26; PMID:21606480;  http://dx.doi.org/10.1182/blood-2010-12-324533.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity 2010; 32:266- 78; PMID:20137985; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
Immunity 2007; 27:635-46;  PMID:17919943; http://dx.doi.org/10.1016/j.immu- ni.2007.08.014.,OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
J Exp Med 1996; 184:1543- 7; PMID:8879227; http://dx.doi.org/10.1084/jem.184.4.1543.,Non-OADS,/arxiv_data1/oa_pdf/67/79/onci-1-1507.PMC3525606.pdf
"www.landesbioscience.com OncoImmunology 1517 ReseaR ch papeR ReseaR ch papeR OncoImmunology 1:9, 1517–1526; December 2012; © 2012 Landes Bioscience *Correspondence to: Marjolein van Egmond; Email: m.vanegmond@vumc.nl Submitted: 08/21/12; Revised: 09/18/12; Accepted: 09/19/12http://dx.doi.org/10.4161/onci.22303Introduction Colorectal cancer (CRC) is the most prevalent malignancy of the  digestive tract in men and women in developed countries.",Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Supplemental Material Supplemental material may be found here: http://www.landesbioscience.com/journals/oncoimmunology/article/22303Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Cancer Epidemiol  Biomarkers Prev 2009; 18:1688-94; PMID:19505900;  http://dx.doi.org/10.1158/1055-9965.EPI-09-0090.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
CA Cancer J  Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Lancet 2005; 365:153-65;  PMID:15639298; http://dx.doi.org/10.1016/S0140- 6736(05)17706-X.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Oncologist 2012; 17:201- 11; PMID:22234631; http://dx.doi.org/10.1634/the- oncologist.2011-0300.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Surg Oncol  2006; 94:68-80; PMID:16788948; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Lancet Oncol 2003; 4:760-8;  PMID:14662433; http://dx.doi.org/10.1016/S1470- 2045(03)01282-8.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Ann Surg  2008; 247:85-94; PMID:18156927; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Hepatology 2008; 47:532-43; PMID:18098323; http://dx.doi.org/10.1002/ hep.22013.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Eur J Surg Oncol 2009; 35:942- 50; PMID:19153024; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Ann Oncol 2008; 19:935-8; PMID:18212090;  http://dx.doi.org/10.1093/annonc/mdm583.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Gut  2011; 60:1076-86; PMID:21278144; http://dx.doi.org/10.1136/gut.2010.224717.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Ann Surg  2009; 249:727-34; PMID:19387333; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Dis Colon Rectum 2007; 50:323-30; PMID:17237910; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Cancer Res  2011; 71:1989-98; PMID:21363926; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Langenbecks Arch Surg 2009; 394:293-302; PMID:18546014; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Ann Surg  2006; 243:359-63; PMID:16495701; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Int J Antimicrob Agents 2002; 20:457-60;  PMID:12458141; http://dx.doi.org/10.1016/S0924- 8579(02)00237-6.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Clin Nutr 2007; 26:208-15;  PMID:17208338; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Nat Immunol 2010; 11:373-84; PMID:20404851;  http://dx.doi.org/10.1038/ni.1863.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Microvasc Res 2009; 77:26-34; PMID:19041330;  http://dx.doi.org/10.1016/j.mvr.2008.10.005.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
World J Surg 2008; 32:288- 95; PMID:18074171; http://dx.doi.org/10.1007/s00268-007-9336-4.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Immunol Methods 1994; 174:83-93; PMID:8083541; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Expert Opin Pharmacother  2010; 11:1753-63; PMID:20491547; http://dx.doi.org /10.1517/14656566.2010.493558.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Clin Invest 2012; 122:787- 95; PMID:22378047; http://dx.doi.org/10.1172/ JCI59643.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Hepatology  2000; 31:932-6; PMID:10733550; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Exp Med  2008; 205:915-27; PMID:18362172; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Ann Surg 2005; 241:199-205; PMID:15650626; http://dx.doi.org/10.1097/01.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Anal Chim Acta 2009; 649:8- 23; PMID:19664458; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Cancer Lett 2008; 266:53-9; PMID:18362051; http://dx.doi.org/10.1016/j.canlet.2008.02.031.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Mol Ther 2007; 15:2194-202; PMID:17968355; http://dx.doi.org/10.1038/ sj.mt.6300310.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Int J Cancer 1984; 33:689- 92; PMID:6202647; http://dx.doi.org/10.1002/ ijc.2910330521.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Clin Invest 1973; 52:2745- 56; PMID:4355998; http://dx.doi.org/10.1172/ JCI107470.42.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Cell Mol Biol Lett 2009; 14:248-72;  PMID:19096763; http://dx.doi.org/10.2478/s11658- 008-0048-z.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
T rends Immunol 2009; 30:475-87; PMID:19781994;  http://dx.doi.org/10.1016/j.it.2009.07.009.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Nat Immunol 2010; 11:889-96;  PMID:20856220; http://dx.doi.org/10.1038/ni.1937.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Crit Care 2006; 10:233;  PMID:17044947; http://dx.doi.org/10.1186/cc5055.38.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
Clin Immunol 2008; 127:66- 77; PMID:18262845; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Cancer Res Clin  Oncol 1997; 123:21-4; PMID:8996536; http://dx.doi.org/10.1007/BF01212610.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
J Thorac  Cardiovasc Surg 2005; 130:125-30; PMID:15999051;  http://dx.doi.org/10.1016/j.jtcvs.2004.07.045.,Non-OADS,/arxiv_data1/oa_pdf/b0/90/onci-1-1517.PMC3525607.pdf
"www.landesbioscience.com OncoImmunology 1527 ReseaR ch papeR ReseaR ch papeR OncoImmunology 1:9, 1527–1536; December 2012; © 2012 Landes Bioscience *Correspondence to: Ignacio Melero; Email: imelero@unav.es Submitted: 07/27/12; Revised: 10/08/12; Accepted: 10/09/12http://dx.doi.org/10.4161/onci.22504Introduction Cardiotrophin-1 (CT-1/CTF1) is a member of the interleukin  (IL)-6 family of cytokines, which includes—besides IL-6 and CT -1—IL-11, IL-27, leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), cardiotro - phin-like cytokine (CLC) and neuropoietin (NP).",Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Cytokine Growth Factor  Rev 1996; 7:81-91; PMID:8864356; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
J Leukoc Biol  2010; 88:1145-56; PMID:20610800; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Gastroenterology  2003; 125:192-201; PMID:12851883; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Hepatology 2005; 41:460- 9; PMID:15723445; http://dx.doi.org/10.1002/ hep.20590.5.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Hepatology 2007; 45:639-48; PMID:17326158;  http://dx.doi.org/10.1002/hep.21508.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Liver  Int 2008; 28:622-31; PMID:18312290; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Cancer Res 2009; 69:2523-30; PMID:19244121; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Nat Rev Clin Oncol 2010; 7:318-25; PMID:20440283;  http://dx.doi.org/10.1038/nrclinonc.2010.62.,OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Future Oncol 2011; 7:1299-323; PMID:22044204;  http://dx.doi.org/10.2217/fon.11.108.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Nat Rev Cancer 2012; 12:298-306;  PMID:22419253; http://dx.doi.org/10.1038/nrc3245.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
J Clin Oncol 2009; 27:5944- 51; PMID:19858404; http://dx.doi.org/10.1200/ JCO.2008.19.6147.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Cancer Res 2009; 69:2685-93; PMID:19258510;  http://dx.doi.org/10.1158/0008-5472.CAN-08-2654.16.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Int J Cancer 2011;  128:2527-35; PMID:21365651; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Am J Surg 1992; 164:176-7;  PMID:1636899; http://dx.doi.org/10.1016/S0002- 9610(05)80380-0.,OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
J Leukoc Biol 2006; 80:227-36; PMID:16707558;  http://dx.doi.org/10.1189/jlb.1105674.,OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Annu  Rev Immunol 2009; 27:147-63; PMID:19302037; http://dx.doi.org/10.1146/annurev.immu- nol.021908.132629.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Nat Med 2005; 11:1314-21;  PMID:16288283; http://dx.doi.org/10.1038/nm1325.,OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Nat Rev Immunol 2007; 7:41-51;  PMID:17186030; http://dx.doi.org/10.1038/nri1995.25.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Cancer  J 2011; 17:351-8; PMID:21952286; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Int J Cancer 2011; 128:105- 18; PMID:20309938; http://dx.doi.org/10.1002/ijc.25333.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
Mol Ther 2012; 20:1664- 75; PMID:22735380; http://dx.doi.org/10.1038/ mt.2012.56.,OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
J Clin Invest  1999; 104:1077-85; PMID:10525046; http://dx.doi.org/10.1172/JCI6265.,Non-OADS,/arxiv_data1/oa_pdf/4a/c4/onci-1-1527.PMC3525608.pdf
"www.landesbioscience.com OncoImmunology 1537 ReseaR ch papeR ReseaR ch papeR OncoImmunology 1:9, 1537–1545; December 2012; © 2012 Landes Bioscience *Correspondence to: Jörg Westermann; Email: joerg.westermann@charite.de Submitted: 07/20/12; Revised: 10/15/12; Accepted: 10/15/12http://dx.doi.org/10.4161/onci.22563Introduction Genetic immunization using naked plasmid DNA is attract - ing increasing interest in tumor immunology since DNA vac - cines combine many desirable attributes, particularly under the  aspect of clinical applicability.",Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Cancer T reat Res  2005; 123:137-56; PMID:16211869; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Nat Rev Cancer 2008; 8:108-20;  PMID:18219306; http://dx.doi.org/10.1038/nrc2326.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Oncoimmunology 2012; 1:316-25; PMID:22737607; http://dx.doi.org/10.4161/ onci.19127.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Adv Immunol 2006; 90:175- 213; PMID:16730264; http://dx.doi.org/10.1016/ S0065-2776(06)90005-4.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Int J Cancer 2004; 109:259- 64; PMID:14750178; http://dx.doi.org/10.1002/ ijc.11654.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Exp Med  1981; 154:952-63; PMID:6974221; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Immunity 2000; 13:265-76; PMID:10981969; http://dx.doi.org/10.1016/S1074-7613(00)00026-1.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Vaccine  2003; 21:4036-42; PMID:12922140; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Int J Pharm 2010; 396:11- 6; PMID:20621704; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Vaccine 2011; 29:9544-50; PMID:21986218; http://dx.doi.org/10.1016/j.vac- cine.2011.09.097.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
BMC Biotechnol 2002; PMID:12028591; 2:10.http://dx.doi.org/10.1186/1472-6750-2-10.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Control Release 2004; 97:527-35; PMID:15212884; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Immunol 2011; 186:1377-83; PMID:21187444; http://dx.doi.org/10.4049/jimmu- nol.1002557.24.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Invest Dermatol 1980; 74:77-80; PMID:6985948;  http://dx.doi.org/10.1111/1523-1747.ep12519909.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Gene Ther 2001; 8:173-80; PMID:11313788;  http://dx.doi.org/10.1038/sj.gt.3301350.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Mol Ther 2005; 12:1176- 84; PMID:16202659; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Mol Biotechnol 2004; 28:121-8; PMID:15477651;  http://dx.doi.org/10.1385/MB:28:2:121.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Clin Cancer Res  2008; 14:7545-53; PMID:19010873; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Ann Oncol 2006; 17:750-62;  PMID:16293674; http://dx.doi.org/10.1093/annonc/ mdj083.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Immunotherapy 2010; 2:213-26;  PMID:20635929; http://dx.doi.org/10.2217/imt.09.89.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Clin Cancer Res 2008; 14:797-803;  PMID:18245541; http://dx.doi.org/10.1158/1078- 0432.CCR-07-1448.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Gene Med 2012; 14:128-37;  PMID:22228591; http://dx.doi.org/10.1002/jgm.1651.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Cancer Gene  Ther 2012; 19:69-76; PMID:21997231; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Vaccine  2003; 21:649-58; PMID:12531334; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Vaccine 2011; 29:3341-55;  PMID:20713100; http://dx.doi.org/10.1016/j.vac- cine.2010.08.002.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Vaccine 2007; 25:3731-41;  PMID:17350735; http://dx.doi.org/10.1016/j.vac- cine.2007.01.120.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Science 1990; 247:1465-8; PMID:1690918;  http://dx.doi.org/10.1126/science.1690918.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Drug  News Perspect 2010; 23:647-53; PMID:21180650;  http://dx.doi.org/10.1358/dnp.2010.23.10.1513492.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Curr Opin  Virol 2011; 1:233-40; PMID:22440782; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Vaccine  2011; 29:6771-80; PMID:21199706; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Immunol  Methods 1994; 175:11-22; PMID:7930633; http://dx.doi.org/10.1016/0022-1759(94)90327-1.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Gene Ther 1999; 6:1785- 7; PMID:10516730; http://dx.doi.org/10.1038/ sj.gt.3301002.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Nat Med 2005; 11:899-904;  PMID:15965482; http://dx.doi.org/10.1038/nm1264.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Nat Med 1996; 2:1122-8;  PMID:8837611; http://dx.doi.org/10.1038/nm1096- 1122.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Exp Med  1998; 188:1075-82; PMID:9743526; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J  Invest Dermatol 2001; 116:313-8; PMID:11180009;  http://dx.doi.org/10.1046/j.1523-1747.2001.01247.x.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
J Immunol Methods 2002; 259:33-42;  PMID:11730839; http://dx.doi.org/10.1016/S0022- 1759(01)00487-2.56.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Curr  Opin Immunol 2011; 23:146-52; PMID:20970973;  http://dx.doi.org/10.1016/j.coi.2010.09.008.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Immunity 2003;  19:5-8; PMID:12871634; http://dx.doi.org/10.1016/ S1074-7613(03)00182-1.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Nat Rev Immunol 2005; 5:251-60;  PMID:15738955; http://dx.doi.org/10.1038/nri1569.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
Semin Immunol 2010; 22:144-54; PMID:20413326;  http://dx.doi.org/10.1016/j.smim.2010.03.004.,OADS,/arxiv_data1/oa_pdf/b6/cc/onci-1-1537.PMC3525609.pdf
"OncoImmunology 1:9, 1546–1556; December 2012; © 2012 Landes Bioscience ReseaR ch papeR 1546 OncoImmunology Volume 1 Issue 9*Correspondence to: Douglas G. McNeel; Email: dm3@medicine.wisc.edu Submitted: 09/21/12; Revised: 10/12/12; Accepted: 10/15/12http://dx.doi.org/10.4161/onci.22564Introduction Prostatic acid phosphatase (PAP) is a prostate cancer-associated  tumor antigen.",Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
N Engl J Med 2010; 363:411-22;  PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294.,OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Cancer Immunol  Immunother 2007; 56:885-95; PMID:17102977;  http://dx.doi.org/10.1007/s00262-006-0241-8.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
J Clin Oncol  2009; 27:4047-54; PMID:19636017; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
J Immunother 2010; 33:639-47; PMID:20551832; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
J Exp Med 1999; 190:1717-22; PMID:10587362; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Surgery 2000; 128:273- 80; PMID:10923004; http://dx.doi.org/10.1067/ msy.2000.107421.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Int J Cancer 2005; 116:415- 21; PMID:15800947; http://dx.doi.org/10.1002/ ijc.21014.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Expert Rev Anticancer Ther 2010; 10:1055- 68; PMID:20645695; http://dx.doi.org/10.1586/ era.10.46.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Int Immunol 1996; 8:1825-32; PMID:8982766;  http://dx.doi.org/10.1093/intimm/8.12.1825.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Immunogenetics  1997; 45:278-9; PMID:9002449; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Cancer Gene Ther 2006; 13:436- 44; PMID:16276349; http://dx.doi.org/10.1038/ sj.cgt.7700914.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Vaccine 2004; 22:1700-8; PMID:15068853;  http://dx.doi.org/10.1016/j.vaccine.2003.10.048.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
J Immunother 2011; 34:569- 80; PMID:21904219; http://dx.doi.org/10.1097/ CJI.0b013e31822b5b1d.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Cancer Immunol  Immunother 2010; 59:943-53; PMID:20140431;  http://dx.doi.org/10.1007/s00262-010-0820-6.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Prostate 1998; 36:129- 38; PMID:9655265; http://dx.doi.org/10.1002/ (SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D. 25.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
J Immunol Methods 2000; 244:29-40;  PMID:11033016; http://dx.doi.org/10.1016/S0022- 1759(00)00249-0.28.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Prostate 2012; 72:730- 40; PMID:22529020; http://dx.doi.org/10.1002/ pros.21477.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Arch  Androl 1978; 1:221-6; PMID:83814; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Cancer Res 2005; 65:6435-42;  PMID:16024648; http://dx.doi.org/10.1158/0008- 5472.CAN-05-0133.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
Clin Cancer Res 2005; 11:6933-43;  PMID:16203785; http://dx.doi.org/10.1158/1078-0432.CCR-05-0682.,Non-OADS,/arxiv_data1/oa_pdf/94/b2/onci-1-1546.PMC3525610.pdf
"www.landesbioscience.com OncoImmunology 1557OncoImmunology 1:9, 1557–1576; December 2012; © 2012 Landes BioscienceREVIEW  REVIEW *Correspondence to: Guido Kroemer and Lorenzo Galluzzi;   Email: kroemer@orange.fr and deadoc@vodafone.itSubmitted: 10/02/12; Accepted: 10/02/12http://dx.doi.org/10.4161/onci.22428Prophylactic vaccination constitutes one of the most prominent  medical achievements of history.",Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
"In line with thin notion, official documents report that Cervarix ® is not efficient  against histopathological endpoints in HPV-infected women (source http://www.fda.gov).",Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
"203,204 Conversely, E7-derived  peptides induced potent immune responses that, in one trial, led to viral clearance from cervical scrapings by the fourth vac - cine course, 200 yet were unable to promote efficient antitumor  immunity.137,200–202 These results are in line with the fact that— according to official sources—preventive anti-HPV vaccines (i.e., Cervarix ® and Gardasil®) are not efficient against histopathologi - cal endpoints when used as therapeutic agents in HPV-infected women (source http://www.fda.gov).",Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Front Immunol 2011; 2:21; PMID:22566811; http://dx.doi.org/10.3389/fimmu.2011.00021.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Med 2003; 9:269-77; PMID:12612576;  http://dx.doi.org/10.1038/nm0303-269.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Front Immunol 2012; 3:68; PMID:22566949; http://dx.doi.org/10.3389/fimmu.2012.00068.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
N Engl J Med  1980; 303:1263-73; PMID:6252467; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Dev Immunol  2011; 2011:609579; PMID:22110526; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
JAMA 1986; 256:3117- 24; PMID:3491225; http://dx.doi.org/10.1001/ jama.1986.03380220083027.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
JAMA 1994; 271:907-13; PMID:8120958; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology 2012; 1:699-716;  PMID:22934262; http://dx.doi.org/10.4161/ onci.20696.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
OncoImmunology 2012; 1: In press; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Science 2010; 327:1345-50;  PMID:20223979; http://dx.doi.org/10.1126/sci- ence.1177319.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Curr Opin Immunol 2004; 16:127-9; PMID:15023402; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 1986; 4:119- 45; PMID:3518743; http://dx.doi.org/10.1146/annurev.iy.04.040186.001003.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Immunol Today 1989; 10:283-6; PMID:2590379;  http://dx.doi.org/10.1016/0167-5699(89)90081-9.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 1994; 12:991-1045;  PMID:8011301; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat  Rev Drug Discov 2012; 11:215-33; PMID:22301798;  http://dx.doi.org/10.1038/nrd3626.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2012; 12:298-306;  PMID:22419253; http://dx.doi.org/10.1038/nrc3245.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Science 1991; 254:1643- 7; PMID:1840703; http://dx.doi.org/10.1126/sci-ence.1840703.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Immunol Today 1993; 14:536-8; PMID:8274196; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Immunol 2001; 1:209-19; PMID:11905830;  http://dx.doi.org/10.1038/35105075.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 1994; 12:337-65;  PMID:8011285; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 2007; 25:267-96;  PMID:17134371; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 2009; 27:83-117;  PMID:19007331; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2012; 12:265-77;  PMID:22437871; http://dx.doi.org/10.1038/nrc3258.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer  2010; 10:707-19; PMID:20865011; http://dx.doi.org/10.1038/nrc2888.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer  2010; 10:550-60; PMID:20592731; http://dx.doi.org/10.1038/nrc2886.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2010; 10:878-89; PMID:21102637; http://dx.doi.org/10.1038/nrc2961.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
T ransplantation  2009; 88:1025-9; PMID:19855249; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Gastroenterology  2008; 134:1385-95; PMID:18471515; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Sci 2009; 100:1935-42; PMID:19604246;  http://dx.doi.org/10.1111/j.1349-7006.2009.01256.x.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Lancet 2009; 374:301-14;  PMID:19586656; http://dx.doi.org/10.1016/S0140- 6736(09)61248-4.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
N Engl J Med 2007; 356:1915- 27; PMID:17494925; http://dx.doi.org/10.1056/ NEJMoa061741.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Hum Vaccin 2009; 5:705-19; PMID:19684472;  http://dx.doi.org/10.4161/hv.5.10.9518.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
N Engl J Med 2010; 363:411-22;  PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology 2012; 1:579- 80; PMID:22934249; http://dx.doi.org/10.4161/ onci.20730.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Res 2012; 72:1081-91;  PMID:22237626; http://dx.doi.org/10.1158/0008- 5472.CAN-11-3722.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Curr Opin Immunol  2011; 23:330-6; PMID:21482090; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2008; 8:351-60;  PMID:18418403; http://dx.doi.org/10.1038/nrc2373.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol  2003; 21:685-711; PMID:12615891; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Immunol 2005; 6:280-6; PMID:15685176; http://dx.doi.org/10.1038/ni1165.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Immunity  2007; 26:629-41; PMID:17509906; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunol 2010; 185:2790-9; PMID:20686126;  http://dx.doi.org/10.4049/jimmunol.0903740.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cell Cycle 2012; 11:1059;  PMID:22343921; http://dx.doi.org/10.4161/ cc.11.6.19746.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Front  Oncol 2011; 1:1; PMID:22655224; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Immunol 2010; 10:490-500;  PMID:20559327; http://dx.doi.org/10.1038/nri2785.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Immunol 2012; 12:253-68; PMID:22437938;  http://dx.doi.org/10.1038/nri3175.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 2009; 27:451-83;  PMID:19105661; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Immunol  2008; 8:958-69; PMID:19029990; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncogene 2007; 26:3594- 602; PMID:17530013; http://dx.doi.org/10.1038/ sj.onc.1210371.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Annu Rev Immunol 2008; 26:481- 511; PMID:18304001; http://dx.doi.org/10.1146/ annurev.immunol.26.021607.090236.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Med 1999; 5:1171-7;  PMID:10502821; http://dx.doi.org/10.1038/13928.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
N Engl J Med 1982; 306:517- 22; PMID:6173751; http://dx.doi.org/10.1056/NEJM198203043060906.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Med 1996; 2:1038-41; PMID:8782465; http://dx.doi.org/10.1038/nm0996-1038.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Front Biosci 2006; 11:337-43;  PMID:16146735; http://dx.doi.org/10.2741/1801.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J T ransl Med 2011; 9:168;  PMID:21970318; http://dx.doi.org/10.1186/1479- 5876-9-168.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Rev Neurol (Paris)  2011; 167:729-36; PMID:21890156; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology 2012; 1:326-33; PMID:22737608;  http://dx.doi.org/10.4161/onci.18852.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2010; 33:83-91; PMID:19952953;  http://dx.doi.org/10.1097/CJI.0b013e3181b8f421.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2005; 5:615-25; PMID:16034368;  http://dx.doi.org/10.1038/nrc1669.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Immunol Rev 2006; 213:66-81; PMID:16972897;  http://dx.doi.org/10.1111/j.1600-065X.2006.00438.x.44.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Adv Cancer Res 2011; 110:107-39; PMID:21704230;  http://dx.doi.org/10.1016/B978-0-12-386469- 7.00005-0.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Semin Immunol 1996; 8:289-93; PMID:8956457;  http://dx.doi.org/10.1006/smim.1996.0037.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J  Cancer 1994; 56:40-5; PMID:7903287; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Immunol Immunother 2009; 58:1449-57;  PMID:19360407; http://dx.doi.org/10.1007/s00262-009-0703-x.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Exp Med 1996;  183:1357-65; PMID:8666894; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Clin Oncol  2005; 23:5099-107; PMID:15983396; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Expert Rev Vaccines 2012; 11:133- 44; PMID:22309662; http://dx.doi.org/10.1586/erv.11.177.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer  2009; 9:675-81; PMID:19701243; http://dx.doi.org/10.1038/nrc2717.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Allergy Proc 1989;  10:387-91; PMID:2697632; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Lung Cancer 2007; 58:88- 94; PMID:17599645; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Neurosurg 2008; 108:963- 71; PMID:18447714; http://dx.doi.org/10.3171/JNS/2008/108/5/0963.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2011; 17:6847-57;  PMID:21918169; http://dx.doi.org/10.1158/1078- 0432.CCR-11-1385.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer  2009; 9:463-75; PMID:19536107; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2010; 10:760-74; PMID:20966921;  http://dx.doi.org/10.1038/nrc2947.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Brain Pathol  2009; 19:713-23; PMID:19744042; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Brain 2012; 135:1042-54;  PMID:22418738; http://dx.doi.org/10.1093/brain/ aws042.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Lung Cancer  2009; 10:371-4; PMID:19808198; http://dx.doi.org/10.3816/CLC.2009.n.052.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer 2012; 118:2594-602; PMID:21989902;  http://dx.doi.org/10.1002/cncr.26574.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J T ransl  Med 2008; 6:24; PMID:18471305; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res  2011; 17:3408-19; PMID:21300761; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Ann Oncol 2012; 23:338-45;  PMID:21543625; http://dx.doi.org/10.1093/annonc/ mdr154.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Biother  Radiopharm 2000; 15:495-505; PMID:11155821; http://dx.doi.org/10.1089/cbr.2000.15.495.107.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Proc Natl Acad Sci U S A  2008; 105:10131-6; PMID:18645180; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Clin  Oncol 2011; 29:2787-94; PMID:21632504; http://dx.doi.org/10.1200/JCO.2010.33.3005.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res  2005; 11:4460-8; PMID:15958631; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer  2007; 109:77-83; PMID:17133412; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Lett 2012; 324:126-32;  PMID:22634429; http://dx.doi.org/10.1016/j.can- let.2012.05.011.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Rev Cancer 2009; 9:874-85;  PMID:19935676; http://dx.doi.org/10.1038/nrc2761.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Immunity 1999; 10:673-9;  PMID:10403642; http://dx.doi.org/10.1016/S1074- 7613(00)80066-7.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Blood  2003; 102:571-6; PMID:12576330; http://dx.doi.org/10.1182/blood-2002-08-2554.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Clin Oncol  2002; 20:2624-32; PMID:12039923; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2005; 11:5900-11;  PMID:16115932; http://dx.doi.org/10.1158/1078-0432.CCR-05-0559.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Immunol  Immunother 2006; 55:1553-64; PMID:16491401;  http://dx.doi.org/10.1007/s00262-006-0145-7.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cell Stress Chaperones 2007; 12:33-43;  PMID:17441505; http://dx.doi.org/10.1379/CSC- 218R.1.93.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology  2012; 1:306-15; PMID:22737606; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology 2012;  1:28-37; PMID:22720209; http://dx.doi.org/10.4161/ onci.1.1.17938.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology 2012; 1:493-506;  PMID:22754768; http://dx.doi.org/10.4161/ onci.20459.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Oncoimmunology 2012; 1:179-88; PMID:22720239;  http://dx.doi.org/10.4161/onci.1.2.19026.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Hematol 2007; 85:426- 9; PMID:17562620; http://dx.doi.org/10.1532/ IJH97.06194.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J T ransl Med 2010; 8:5;  PMID:20092642; http://dx.doi.org/10.1186/1479- 5876-8-5.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Pediatr Blood Cancer 2010; 55:352- 5; PMID:20582983; http://dx.doi.org/10.1002/ pbc.22522.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Blood 2009; 113:6541-8; PMID:19389880; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Haematologica 2010; 95:1191-7; PMID:20081055;  http://dx.doi.org/10.3324/haematol.2009.014704.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Blood  2008; 111:1357-65; PMID:17978170; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Clin Oncol  2003; 21:4016-26; PMID:14581425; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2004; 10:5004-13;  PMID:15297401; http://dx.doi.org/10.1158/1078- 0432.CCR-04-0241.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
PLoS Med 2005; 2:e265;  PMID:16162034; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Am J Clin Oncol 2006; 29:352-60; PMID:16891861;  http://dx.doi.org/10.1097/01.coc.0000217877.78473.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Biother Radiopharm 2007; 22:551- 5; PMID:17803450; http://dx.doi.org/10.1089/ cbr.2007.376.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2007; 30:234-9; PMID:17471170; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res  2007; 13:6386-95; PMID:17975151; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer 2009; 124:130-9; PMID:18839429;  http://dx.doi.org/10.1002/ijc.23886.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2009; 15:7036-44; PMID:19903780;  http://dx.doi.org/10.1158/1078-0432.CCR-09-1544.146.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer  2012; 130:584-92; PMID:21413013; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Proc Natl Acad Sci U S  A 1999; 96:5710-5; PMID:10318949; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Prostate  2004; 60:32-45; PMID:15129427; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer  Sci 2004; 95:77-84; PMID:14720331; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Prostate 2005;  63:1-12; PMID:15378520; http://dx.doi.org/10.1002/ pros.20157.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Prostate  2003; 57:80-92; PMID:12886526; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Prostate  2009; 69:917-27; PMID:19267352; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Sci  2010; 101:601-8; PMID:20128819; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer 1997;  74:193-8; PMID:9133455; http://dx.doi.org/10.1002/(SICI)1097-0215(19970422)74:2<193::AID- IJC10>3.0.CO;2-F .,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Adv Immunol 2006; 90:243-95;  PMID:16730266; http://dx.doi.org/10.1016/S0065-2776(06)90007-8.134.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother  1999; 22:54-66; PMID:9924700; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Front Biosci  2002; 7:e48-57; PMID:11815284; http://dx.doi.org/10.2741/ghader.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother  2004; 27:60-72; PMID:14676634; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer 2012; 131:E670- 80; PMID:22139992; http://dx.doi.org/10.1002/ijc.27388.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Proc Natl Acad Sci U S A  2012; 109:5797-802; PMID:22454499; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Am Coll Surg 2009; 208:193-201;  PMID:19228530; http://dx.doi.org/10.1016/j.jam - collsurg.2008.10.018.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2010; 16:3495-506;  PMID:20466887; http://dx.doi.org/10.1158/1078- 0432.CCR-10-0085.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2009; 32:655-66; PMID:19483644; http://dx.doi.org/10.1097/CJI.0b013e3181a80e0d.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Immunol  Immunother 2006; 55:1033-42; PMID:16283303;  http://dx.doi.org/10.1007/s00262-005-0090-x.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer  2007; 120:2178-84; PMID:17278093; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Sci  2007; 98:1113-9; PMID:17459063; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer 2008; 123:2362-9; PMID:18729190; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
First clinical trial of cancer vac-cine therapy with artificially synthesized helper/?killer- hybrid epitope long peptide of MAGE-A4 cancer anti- gen. Cancer Sci 2012; 103:150-3; PMID:22221328;  http://dx.doi.org/10.1111/j.1349-7006.2011.02106.x.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J T ransl Med 2012; 10:141; PMID:22776426;  http://dx.doi.org/10.1186/1479-5876-10-141.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Sci 2009; 100:1502-9; PMID:19459850; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2000; 23:255-66; PMID:10746552;  http://dx.doi.org/10.1097/00002371-200003000-00010.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Sci  2007; 98:1965-8; PMID:17919310; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Nat Med 2012; In press; PMID:22842478;  http://dx.doi.org/10.1038/nm.2883.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2008; 31:781- 91; PMID:18779741; http://dx.doi.org/10.1097/ CJI.0b013e318183af0b.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer  Res 2009; 69:1046-54; PMID:19176376; http://dx.doi.org/10.1158/0008-5472.CAN-08-2926.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2011; 17:4568-80;  PMID:21586625; http://dx.doi.org/10.1158/1078- 0432.CCR-11-0184.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Proc Natl Acad Sci U S A  2007; 104:8947-52; PMID:17517626; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Melanoma Res 2002; 12:505-11; PMID:12394193;  http://dx.doi.org/10.1097/00008390-200209000- 00013.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int Immunol 2003; 15:1423-30; PMID:14645151; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Br J Cancer 2004; 90:1334- 42; PMID:15054451; http://dx.doi.org/10.1038/ sj.bjc.6601711.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Immunol Immunother  2006; 55:1294-8; PMID:16315030; http://dx.doi.org/10.1007/s00262-005-0102-x.170.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2010; 33:630- 8; PMID:20551833; http://dx.doi.org/10.1097/ CJI.0b013e3181e311ac.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
N Engl J Med 2011; 364:2119- 27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863.,OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2007; 30:240-50; PMID:17471171; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2009; 32:875-83; PMID:19752746;  http://dx.doi.org/10.1097/CJI.0b013e3181b56ad9.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer Res 2011; 17:2987-96;  PMID:21385924; http://dx.doi.org/10.1158/1078- 0432.CCR-10-3272.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother  2000; 23:275-81; PMID:10746554; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Int J Cancer 2003; 104:188-94; PMID:12569574; http://dx.doi.org/10.1002/ ijc.10961.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother  2004; 27:472-7; PMID:15534491; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
J Immunother 2003;  26:357-66; PMID:12843798; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Clin Cancer  Res 2008; 14:169-77; PMID:18172268; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Ann Oncol 2008; 19:1657-8; PMID:18647966;  http://dx.doi.org/10.1093/annonc/mdn430.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
Cancer Immunol Immunother 2011; 60:15- 22; PMID:21080166; http://dx.doi.org/10.1007/s00262-010-0940-z.,Non-OADS,/arxiv_data1/oa_pdf/12/2c/onci-1-1557.PMC3525611.pdf
